Home | Databases | WorldLII | Search | Feedback Vanuatu Consolidated Subsidiary Legislation

Sale of Medicines Regulations

Commencement: 27 June 1988

SALE OF MEDICINES REGULATIONS

Order 25 of 1988
Order 32 of 2005

To regulate the sale of medicines.

1. Interpretation
In these regulations unless the context otherwise requires:

“child-resistant closure” means –

(a) a closure which is resistant to opening by children;

(b) in the case of a can fitted with a press-on lid, a lid of the design known as "double tight" or "triple tight";

“dosage unit” means an individual dose of a medicine and includes a tablet, capsule, cachet, single dose powder or single dose sachet of powders or granules;

“essential drug list” means a list of medicines outlined by the Ministry of Health to meet the priority health care needs of the population;

“internal use” means administration –

(a) orally, except for topical effect in the mouth; or

(b) for absorption and the production of a systemic effect –

by way of a body orifice other than the mouth; or

(ii) parenterally, other than by application to unbroken skin;

“medicine” means any substance or preparation which is included in the Schedules;

“primary pack” means the pack in which a medicine and its immediate container or immediate wrapper or measure pack are presented for sale or supply; and

(a) “immediate container” includes all forms of containers in which a medicine is directly packed but does not include any such container intended for consumption or any immediate wrapper;

(b) “immediate wrapper” means metal foil, plastic foil, waxed paper, or any such material not intended for consumption, when used as the first wrapper for a dosage unit which contains any medicine;

(c) “measure pack” means one of two or more sealed containers each of which contains a measured quantity of medicine for use on one occasion as a pesticide and which forms part of a single primary pack;

“sell” includes exposing or offering for sale or having in possession for sale, whether by wholesale or retail, and also includes delivery with or without consideration;

“therapeutic use” means use in or in connection with –

(a) the preventing, diagnosing, curing or alleviating of a disease, ailment, defect or injury in human beings or animals;

(b) the influencing, inhibiting or modifying of a physiological process in human beings or animals; or

(c) the testing of the susceptibility of human beings or animals to a disease or ailment;

“topical use” means application of a medicine for the purpose of producing a localised effect on the surface of the organ or within the tissue to which it is applied;

“wholesaler” means a person who imports, sells or otherwise supplies a medicine for resale.

2. Sale of medicines
(1) A person may sell any medicine listed in Schedule 1.

(2) A person referred to in subregulation (1) must not sell a medicine listed in schedule 1 unless the medicine is adequately labelled to ensure its appropriate and safe use.

(3) The medicines listed in Schedules 2 and 3 must not be sold by any person other than the following persons:

(a) a pharmacist;

(b) a druggist;

(c) a medical practitioner;

(d) a veterinary surgeon;

a dental practitioner.

(4) A pharmacist or a druggist may sell any medicine listed under Schedule 3 only upon the prescription of:

(a) a medical practitioner; or

(b) a dental practitioner.

(5) A veterinary surgeon may only sell a medicine listed in schedule 2 or 3 if the medicine is for the treatment of animals.

(6) A dental practitioner may only sell a medicine listed in schedule 2 or 3 if the medicine relates to the practice of dentistry.

(7) A wholesaler approved by the Ministry of Health may only sell a medicine listed in schedule 2 or 3 to the persons mentioned in subregulation (3).

(8) Despite subregulation (3), a person approved by the Ministry of Health may supply a medicine listed on the Essential Drug List within the normal course of his or her duties.

2A. Urgent supply
(1) Despite regulation 2(4), a pharmacist may sell a medicine listed under Schedule 3 to a person who visits Vanuatu on a tourist visa if the pharmacist is satisfied that the person:

(a) is under a medical treatment which requires him or her to use the medicine continuously for the period of the treatment; and

(b) has not brought the medicine with him or her during the period of the visit.

(2) A pharmacist referred to in subregulation (1) may sell a sufficient supply of medicine for the duration of a maximum period of 32 days to a person who meets the criteria under paragraphs (a) and (b) of subregulation (1).

(3) A pharmacist may sell a 3 day supply of a medicine listed under Schedule 3 to a resident if the pharmacist is satisfied that the resident:

(a) is in urgent need for the medicine; and

(b) is under medical treatment that requires the use of the medicine; and

(c) requires continuous treatment for his wellbeing.

3. Notices
(1) The Principal Pharmacist may issue such notices as he deems fit for the proper carrying out of these regulations.

(2) Any notice issued under this regulation shall be published in the Gazette.^[1]

SCHEDULE 1

AMMONIATED MERCURY
ALGINIC ACID and ALGINATE
ALMOND OIL
ALUMINIUM CARBONATE
ALUMINIUM HYDROXIDE in preparations for oral use.
ALUMINIUM OXIDE
AMINACRINE for use in dental gels.
AMINOACETIC ACID
AMINOBENZOIC ACID for external use.
AMMONIUM CHLORIDE mixture.
AMMONIUM ACETATE strong solution.
AMYLMETOCRESOL for use in oral pastilles.
ANISE OIL
ANTACIDS
ARACHIS OIL
ARNICA preparations for external use.
ASCORBIC ACID
ASPIRIN

(a) except when included in Schedule 3;
(b) when in individually wrapped powders or sachets of granules each containing 650 milligrams or less of aspirin as the only therapeutically active constituent when –

(i) the pack is labelled with the warning statement-

WARNING - THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD; or

CAUTION-THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY

AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL; and

(ii) in a primary pack containing not more than 12 such powders or sachets of granules, or

(c) when in tablets or capsules each containing 325 milligrams or less of aspirin as the only therapeutically active constituent when –

(i) the pack is labelled with the warning statement –

WARNING-THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE. AMOUNTS OR FOR A LONG PERIOD; or

CAUTION-THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL

(ii) packed in blister or strip packaging or in containers with a child-resistant closure; and

(iii) in a primary pack containing not more than 25 such tablets or capsules, or

(d) when compounded with codeine as per schedule 1 entry for codeine.

AZADIRACHTA INDICA extracts (neem extracts), extracted from neem seed kernels using water, methanol or ethanol, in preparations containing 5 per cent or less of total limonoids, for agricultural use.
BASIL OIL
BAY OIL
BEESWAX

BENZAMINE when included in –

(a) lozenges, pastilles, tablets or capsules containing 30 mg or less of benzamine in each; or
(b) suppositories or bougies containing 200 mg or less of benzamine in each; or
(c) preparations for external use, other than eye drops, containing 10 per cent or less of benzamine.

BENZOCAINE when included in –

(a) lozenges, pastilles, tablets or capsules containing 30 mg or less of benzocaine in each; or
(b) suppositories or bougies containing 200 mg or less of benzocaine in each; or
(c) preparations for external use, other than eye drops, containing 10 per cent or less of benzocaine.

BENZOIC ACID for external use.
BENZALKONIUM CHLORIDE as lozenges or in preparations for external use
BENZOYL PEROXIDE in preparations for external human therapeutic use containing 5 per cent or less of benzoyl peroxide.
BENZYDAMINE in preparations for topical use containing 3 per cent or less of benzydamine.
BENZYL ALCOHOL for external use.
BENZYL BENZOATE application BP.
BENZYL CINNAMATE for external use.
BERGOMOT OIL
BISMUTH OXIDE for external use.
BORIC ACID and BORAX

BUTYLAMINOBENZOATE when included in –

(a) Lozenges, pastilles, tablets or capsules containing 30 mg or less of butylaminobenzoate in each; or
(b) suppositories or bougies containing 200 mg or less of butylaminobenzoate in each; or
(c) preparations for external use, other than eye drops, containing 10 per cent or less of butylaminobenzoate.

CALAMINE preparations for topical use.
CALCIUM CARBONATE BP
CALCIUM CHLORIDE for oral use.
CALCIUM GLUCONATE for oral use.
CALCIUM LACTATE for oral use.
CALCIUM PHOSPHATE for oral use.
CARDAMOM
CASSIA OIL
CASTOR OIL BP
CARBETAPENTANE except in preparations containing 0.5 per cent or less of carbetapentane.
CETALKONIUM CHLORIDE
CETOMACROGOL for use in external preparations.
CETOSTEARYL ALCOHOL
CETRIMIDE cream, ointment or liquid.
CETYL ALCOHOL
CETYLPYRIDINIUM CHLORIDE

CODEINE when compounded with aspirin, paracetamol or salicylamide or any one of their derivatives, in tablets or capsules each containing 10 mg or less of codeine, and no other analgesic substance, when –

(a) packed in blister or strip packaging or in containers with child-resistant closures;and
(b) in a primary pack containing 25 or less dosage units; and

(c) one pack may only be supplied at a time to one person.

CHAMOMILE extract for external use.
CHLORHEXIDINE solutions for external use (including mouthwash) and other topical products.
CHLOROCRESOL for external use.
CHOLINE SALICYLATE for external use or for teething gels containing 0.9 per cent or less of choline salicylate.
CINEOLE
CINNAMIC ACID (maximum strength 500mcg) or external preparations.
CINNAMON LEAF OIL
CLOVE OIL
COD LIVER OIL preparations.
COLLOIDAL OATMEAL
CREOSOTE, for therapeutic use, except in preparations containing 3 per cent or less of phenols included in Schedule 1.
CROTAMITON for external use.
CUPRIMYXIN for the treatment of animals.
DEMBREXINE in oral preparations for the treatment of animals.
TRANS-4-((3,5-DIBROMO-2-HYDROXYBENZYL) AMINO) CYCLOHEXANOL HYDROCHLORIDE MONOHYDRATE (Sputolysin) in oral preparations for the treatment of animals.
DICHLOROBENZYL ALCOHOL for use in oral pastilles.
DICHLOROPHEN for treatment of animals.
DIMETHICONE for external use.
DIMETHYL SULFOXIDE for the treatment of animals.
DIPHEMANIL METHYLSULPHATE in preparations for topical use.
DITHIAZANINE in preparations containing 2 per cent or less of dithiazanine for the treatment of animals.
DORAMECTIN for external use for the treatment of animals in preparations containing 2 per cent or less of doramectin.
DOCOSAHEXANOIC ACID.
DOCUSATE preparations.
EICOSAPENTAENOIC acid
ETHER except when included in schedule 2 or 3 or in preparations containing 10 per cent or less of ether.
EUCALYPTUS OIL
FENBENDAZOLE for the treatment of animals.
FLUBENDAZOLE for treatment of animals.
FOLIC ACID in preparations for oral use.
FRIARS BALSAM
FULLERS EARTH Powders BP
GLUTARALDEHYDE for human therapeutic use.
GLYCERIN BP
GLYCERIN THYMOL BP
GLYCERYL MONOSTEARATE
GENTIAN VIOLET
GRIPE WATER (alcohol free)
GUAIPHENESIN

(a) when in liquid preparations containing 2 per cent (200 mg/10 mi) or less of guaiphenesin; or
(b) when in divided preparations containing 120 mg or less of guaiphenesin in each dosage unit.

HALIBUT LIVER OILS preparations.
HEPARIN for external use.
HEXACHLOROPHANE in preparations for human skin cleansing purposes containing 3 per cent or less of hexachlorophane except in preparations for use on infants as specified in Schedule 3.
HUMAN CHORIONIC GONADOTROPHIN OR ANTIBODY in pregnancy test kits.
HYDROGEN PEROXIDE solutions in strengths not exceeding 30 vols.
ICHTHAMMOL GLYCERIN
INOSITOL
IODINE except when included in Schedule 2.
IRON COMPOUNDS for human internal use

(a) except when included in Schedule 3;
(b) when in divided preparations containing 5 mg or less of iron per dosage unit; or
(c) when in liquid oral preparations containing 0.1 per cent or less of iron.

ISOPROPYL MYRISTATE for external use
ISPHAGULA HUSK
LACTITOL preparations
LACTULOSE for therapeutic use.
LECITHIN
LEMON OIL
LEVOMENTHOL for inhalation

LIGNOCAINE when included in –

(a) lozenges, pastilles, tablets or capsules containing 30 mg or less of lignocaine in each;
(b) suppositories or bougies containing 200 mg or less of lignocaine in each; or
(c) preparations for external use, other than eye drops, containing 10 per cent or less of lignocaine.

LINDANE in preparations for external human therapeutic use containing 2 per cent or less of lindane.
LIME OIL
LIQUID PARAFFIN
LIQUORICE extract
LUTEINISING HORMONE ANTIBODIES in human ovulation test kits.
MAGNESIUM ALGINATE
MAGNESIUM CARBONATE BP
MAGNESIUM HYDROXIDE BP
MAGNESIUM STEARATE
MAGNESIUM SULPHATE paste
MAGNESIUM TRISILICATE mixture and powder BP
MALDISON in preparations for external human therapeutic use containing 2 per cent or less of maldison.
MERCURY ORGANIC COMPOUNDS for topical therapeutic use in preparations containing 0.5 per cent or less of mercury.
MENTHOL
METHYL SALICYLATE for external use
MILBEMYCIN OXIME for the prophylaxis of heartworm in dogs and cats.
MOXIDECTIN for the treatment of animals.
MULTIVITAMIN preparations see vitamins
MYRRH tincture
NALIDIXIC ACID when packed and labelled for the treatment of ornamental fish.
NETOBIMIN for the treatment of animals
NICOTINAMIDE tablets BP
NICOTINE in preparations containing 3 per cent or less of nicotine when labelled and packed for the treatment of animals.
NONOXYNOL preparations
NUTMEG OIL
OESTRADIOL in implant preparations for growth promotion in animals
OLBAS OIL
OLIVE OIL for therapeutic use
ORAL REHYDRATION sachets
ORANGE OIL
OXANTEL EMBONATE in the treatment of animals
OXFENDAZOLE in the treatment of animals
OXIBENDAZOLE in the treatment of animals
OXYTETRACYCLINE in the treatment of animals
PADIMATE
PHENAZONE in the treatment of animals
PECTIN
PARACETAMOL-

(a) except when included in Schedule 3;

(b) when in individually wrapped powders or sachets of granules each containing 1,000 milligrams or less of paracetamol as the only therapeutically active constituent when –

(i) the pack is labelled with the warning statement –

WARNING - THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD; or

CAUTION - THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL; and

(ii) in a primary pack containing not more than 12 such powders or sachets of granules;

(c) when in tablets or capsules each containing 500 milligrams or less of paracetamol as the only therapeutically active constituent when- –

(i) the pack is labelled with the warning statement –

WARNING - THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD; or

CAUTION - THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL; and

(ii) packed in blister or strip packaging or in containers with a child-resistant closure; and

(iii) in a primary pack containing not more than 25 such tablets or capsules.

(d) when compounded with codeine as per Schedule 1 entry for codeine.

PEPPERMINT OIL capsules
PEROXYL
PETROLEUM JELLY BP white and yellow
PHENOL and any homologue of phenol boiling between 220 C, for human therapeutic use, in preparations containing 3 per cent or less by weight of such substances.

PHENYLEPHRINE except when included in schedule 2 or 3 –
(a) when in preparations containing 0.5 per cent or less of phenylephrine, or
(b) when in preparations for external use containing 1 per cent or less of phenylephrine

PIPERAZINE for animal use.
POLYSORBATES.
POTASSIUM HYDROXIDE for external use.
POTASSIUM THIOCYABATE for external use.
POVIDONE IODINE for external use.
PROFLAVINE HEMISULPHATE for external use.
PROPYLENE GLYCOL for external use.
PYRANTEL for human therapeutic use.
PYRITHIONE ZINC for human therapeutic use, in preparations containing 2 per cent or less of pyrithione zinc, when –

(a) in semisolid hair preparations; or
(b) in shampoos.

SAGE OIL.
SASSAFRAS OIL.
SALICYLIC ACID preparations for topical use in concentrations less than 40%.

SALICYLAMIDE -

(a) except when included in Schedule 3; or

(b) when in individually wrapped powders or sachets of granules each containing 1,000 milligrams or less of salicylamide as the only therapeutically active constituent when –

(i) the pack is labelled with the warning statement –

WARNING – THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD; or

CAUTION – THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL; and

(ii) in a primary pack containing not more than 12 such powders or sachets of granules; or

(c) when in tablets or capsules each containing 500 milligrams or less of salicylamide as the only therapeutically active constituent when –

(i) the pack is labelled with the warning statement –

WARNING – THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD; or

CAUTION – THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL; and

(ii) packed in blister or strip packaging or in containers with a child-resistant closure; and

(iii) in a primary pack containing not more than 25 such tablets or capsules.

(d) when compounded with codeine as per schedule 1 entry for codeine.

SARSAPARILLA
SENNA preparations
SHARK LIVER OIL for external use
SODIUM BICARBONATE except when included in Schedule 3.
SOYA OIL
STERCULIA
SUNFLOWER OIL
SUNSCREEN preparation
SULFACETAMIDE when packed and labelled for the treatment of ornamental caged birds or ornamental fish.
SULFADIAZINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish.
SULFADIMIDINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish.
SULFAMERAZINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish.

SULFAQUINOXALINE when
packed and labelled for use as a coccidiostat in poultry except in preparations containing 200mg/kg or less of sulfaquinoxaline. sulfaquinoxaline when incorporated in:

baits of destruction of vermin; or

animal feeds containing 200mg/kg or less of sulfaquinoxaline; or

when packed and labelled solely for use as a herbicide.

SULFATHIAZOLE when packed and labelled for the treatment of ornamental caged birds or ornamental fish.

TETRACYCLINE
in preparations for topical application to animals for ocular use; or
(b) containing not more than 100,000 IU of tetracycline per dose, for intramammary infusion in animals; or
(c) containing 40 per cent or less of tetracycline, when packed and labelled for the treatment of ornamental caged birds or ornamental fish.

TESTOSTERONE in implant preparations for use in animals.
TETRAMISOLE in preparations for the treatment of animals.
TOLNAFTATE for tinea pedis
TULLE dressing
UNDECANOATES for external use
VITAMINS and MINERAL preparations containing less than 7500 IU vitamin A (retinol) and/or less than 50mg vitamin B6 (pyridoxine) per dosage unit.
WARFARIN in rodent baits containing 0.1 per cent or less of warfarin.
WITCH HAZEL preparations for external use (excluding eye preparations)
XYLOMETAZOLINE drops and sprays
ZINC CARBONATE for external use.
ZINC OXIDE for external use containing 5 per cent or less of zinc.

SCHEDULE 2

ACEPIFYLLINE in liquid oral preparations.
ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80 per cent of acetic acid, for therapeutic use.
ACETYLCYSTEINE as eye drops.
ACICLOVIR in topical preparations containing 5 per cent or less of aciclovir.
ACTIVATED CHARCOAL preparations
ADRENALINE in preparations containing 1 per cent or less of adrenaline except in preparations containing 0.02 percent or less of adrenaline.
ALBENDAZOLE in the treatment of animals
ALCLOMETASONE in preparations for dermal use, as the only therapeutically active agent, containing 0.05 per cent or less of alclometasone.
ALOXIPRIN
ALLANTOIN for external use
ALOES
ALOIN
ALUMINIUM CHLORIDE HEXAHYDRATE for external use
AMETHOCAINE in preparations for topical use, other than eye drops, containing 10 per cent or less of total anaesthetic substances.
AMINOPHYLLINE in liquid oral preparations containing 2 per cent or less of aminophylline.
AMMONIATED MERCURY
AMOROLFINE for topical use in preparations containing 0.25 per cent of less of amorolfine.
ANTAZOLINE in eye drops.
ASPERGUM
ASPIRIN except when included in Schedule 1 or 3.

ATROPINE, except atropine methonitrate included in Schedule 3 –

(a) when in preparations containing 0.25 per cent or less of atropine; or
(b) atropine sulphate, 0.6 mg tablets in packs of 6, when labelled for
treatment of organophosphorus poisoning.

AZATADINE in oral preparations.
AZELAIC ACID in dermal preparations.
AZELASTINE in nasal preparations.
BANDAGES impregnated with anti-bacterial agents.
BECLOMETHASONE in aqueous nasal sprays for the prophylaxis or treatment of allergic rhinitis, for up to 6 months use.
BELLADONNA in preparations containing 0.25 per cent or less of the alkaloids of belladonna, calculated as hyoscyamine.
BENZOYL PEROXIDE in preparations containing 10 per cent or less of benzoyl peroxide for external human therapeutic use, except when included in Schedule 1.
BEPHENIUM SALTS
BIFONAZOLE in preparations for dermal use except in preparations containing 1 per cent or less of bifonazole for the treatment of the scalp.
BISACODYL preparations
BORAX (sodium borate) for therapeutic use
BORIC ACID for external use

BORON for external human therapeutic use:

(a) in glycerines or honeys of borax or boric acid; or
(b) in dusting powders for paediatric use; or
(c) as a therapeutically active ingredient in other preparations for dermal use except:

(i) in antifungal preparations; or
(ii) in preparations containing 0. 1 per cent or less of boron.

BROMHEXINE
BROMPHENIRAMINE in oral preparations
BUCLIZINE in oral preparations.
BUDESONIDE in aqueous nasal sprays for the prophylaxis or treatment of allergic rhinitis, for up to 6 months use.
CADEXOMER-IODINE preparations
CAFFEINE oral preparations for human therapeutic use.
CAMPHOR
CARBARYL in preparations for external human therapeutic use containing 2 per cent or less of carbaryl.
CARBENOXOLONE for oral use.
CARBOCISTEINE.
CARBOMER eye drops/gels.
CARBENOXOLONE for topical oral use
CETIRIZINE in preparations for oral use
CETRIMIDE shampoo
CHLORAL HYDRATE for human internal therapeutic use in preparations containing 5 per cent or less of chloral hydrate, when packed in containers of 100 ml or less
CHLORBUTOL for human use in topical preparations containing more than 0.5 per cent and less than 5 per cent of chlorbutol.
CHLOROCRESOL
CHLOROFLUOROCARBONS - See FLUOROCARBONS

CHLOROFORM in preparations for therapeutic use except –

(a) when included in Schedule 3; or
(b) in preparations containing 0.5 per cent or less of chloroform.

CHLOROQUINE tablet 150mg for uncomplicated malaria, maximum of 3 days treatment.
CHLOROTHYMOL containing products
CHLOROXYLENOL
CHLORPHENIRAMINE in oral preparations.
CHOLINE SALICYLATE for external use
CICLOPIROX in preparations for dermal use.
CIMETIDINE for relief of symptoms of gastro-oesophageal reflux, in packs containing not more than 14 days supply.
CINCHOCAINE for external use other than eye drops.
CINNAMEDRINE
CINNARIZINE
CLEMASTINE in oral preparations.
CLOBETASONE for dermal use
CLOTRIMAZOLE for human use in preparations for dermal or vaginal use.
COAL TAR preparations for external use

CODEINE when compounded with one or more other therapeutically active substances:
(a) in divided preparations containing 15mg or less per dosage unit of codeine and with a recommended dose not exceeding 30mg of codeine; or
(b) in undivided preparations containing 0.25 per cent or less of codeine and with a recommended dose not exceeding 30mg of codeine; or
(c) where the quantity supplied in not more than a reasonable amount for personal use, except when included in Schedule 1.

COTRIMOXAZOLE (trimethoprim with sulfamethoxazole) for minor infections where a maximum of 7 days treatment may be supplied.
CRYSTAL VIOLET
CYPROHEPTADINE in oral preparations.

DATURA spp. for oral use:
(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids; or
(b) in divided preparations containing 0.3mg or less of total solanaceous alkaloids per dosage unit, except if separately specified in these Schedules.

DATURA STRAMONIUM (Stramonium) for oral use;
in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids; or
in divided preparations containing 0.3mg or less of total solanaceous alkaloids per dosage unit,
except for smoking or burning.

DATURA TATULA (Stramonium) for oral use:
in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids; or
in divided preparations containing 0.3mg or less of total solanaceous alkaloids per dosage unit;
except for smoking or burning.

DELPHINIUM STAPHISAGRIA except in preparations containing 0.2 per cent or less of delphinium staphisagria.
DESLORATADINE in preparations for oral use
DEXCHLORPHENIRAMINE in oral preparations
DEXTROMETHORPHAN when compounded with one or more other therapeutically active substances in such a way that the dextromethorphan contained therein cannot be readily extracted, when –

(a) in divided preparations containing 30 mg or less per dosage unit and with a recommended dose not exceeding 30 mg of dextromethorphan; or
(b) in undivided preparations containing 0.3 per cent or less of dextromethorphan with a recommended dose not exceeding 30 mg of dextromethorphan.

DICHLOROPHEN for internal human therapeutic use.

DICLOFENAC when –
oral preparations of 25mg or less per dosage unit in pack size up to 30 dosage units; and
as a preparation for external use.

DICYCLOMINE in preparations containing 0.1 per cent or less dicyclomine.

DIHYDROCODEINE, when compounded with one or more other therapeutically active substances when –

(a) in divided preparations containing 10 mg or less per dosage unit and with a recommended dose not exceeding 15 mg of dihydrocodeine; or
(b) in undivided preparations containing 0.25 per cent or less of dihydrocodeine with a recommended dose not exceeding 15 mg of dihydrocodeine.

DI-IODOHYDROXYQUINOLONE for vaginal use
DIMENHYDRINATE in oral preparations.
DIMETHINDENE in oral preparations.
DIPHENHYDRAMINE in oral preparations.
DIPHENOXYLATE in packs of 8 or less dosage units, each dosage unit containing 2.5mg or less of diphenoxylate and a quantity of atropine sulphate equivalent to at least 1 per cent of the dose of diphenoxylate.
DIPHENYLPYRALINE in oral preparations.
DITHRANOL for human therapeutic use.
DOXYLAMINE in oral preparations.

DUBOISIA LEICHARDTII for oral use.
in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids; or
in divided preparations containing 0.3mg or less of total solanaceous alkaloids per dosage unit.

DUBOISIA MYOPOROIDES for oral use;
in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids; or
in divided preparations containing 0.3mg or less of total solanaceous alkaloids per dosage unit.

ECONAZOLE for human use in preparations for dermal or vaginal use
EPHEDRINE in nasal drops containing 0.5 per cent or less of ephedrine.
ERYTHRITYL TETRANITRATE for therapeutic use.
ERYTHROMYCIN for minor infections where a maximum of 7 days treatment may be supplied.
ETHOHEPTAZINE in preparations containing 1 per cent or less of ethoheptazine.

ETHYLMORPHINE, when compounded with one or more other therapeutically active substances –

(a) in divided preparations containing 10 mg or less per dosage unit and with a recommended dose not exceeding 15 mg of ethylmorphine; or
(b) in undivided preparations containing 0.25 per cent or less of ethylmorphine with a recommended dose not exceeding 15 mg of ethylmorphine.

ETHER for therapeutic use except when included in Schedule 3.
ETOFENAMATE for preparations for external use.
FAMOTIDINE for relief of symptoms of gastro-oesophageal reflux, in packs containing not more than 14 days supply.
FELBINAC in preparations for external use
FENOTEROL in metered aerosols delivering 200 micrograms or less of fenoterol per metered dose.
FEXOFENADINE for oral use
FLAVOXATE

FLUORIDES for human therapeutic use:
Sodium fluoride, in preparations for ingestion containing 2.2 mg or less of sodium fluoride per dosage unit, or in preparations for topical use except –

(i) In dentifrices containing 1,000 mg/kg or less of fluoride ion; or

(ii) In substances containing 15 mg/kg or less of fluoride ion.

FLUCONAZOLE for dermal or vaginal use
FLUNISOLIDE in aqueous nasal sprays for the prophylaxis or treatment of allergic rhinitis, for up to 6 months use.
FLURBIPROFEN in divided preparations for topical or oral use containing 10mg or less of flurbiprofen per dosage unit.
FLUOROCARBONS and CHLOROFLUOROCARBONS alone or in combination with other propellants or refrigerants in liquefied gas form for therapeutic use.
FLUORIDES dentrifices containing more than 1000mg/kg of fluoride ion
FLUTICASONE in nasal spray for prophylaxis or allergic rhinitis for short term use.
FORMALDEHYDE (excluding its derivatives) for human therapeutic use except in preparations containing 5 per cent or less of formaldehyde.
GELSEMIUM SEMPERVIRENS.
GLUTARALDEHYDE for human therapeutic use.
GLUCAGON
GLYCERYL TRINITRATE for therapeutic use except when included in Schedule 3
GLYCOPYRROLATE except when included in Schedule 3.
HEXACHLOROPHANE in preparations for human skin cleansing purposes containing 3 per cent or less of hexachlorophane except in preparations for use on infants as specified in Schedule 3
HOMATROPINE in preparations containing 0.25 per cent or less of homatropine.
HUMAN CHORIONIC GONADOTROPHIN or antibody in pregnancy test kits.

HYDROCORTISONE and HYDROCORTISONE ACETATE Containing 1 per cent or less of hydrocortisone
for dermal use in packs containing 30g or less and containing no other therapeutically active agent except for an antifungal;
for rectal use, in packs containing 35g or less or 12 suppositories or less but no other therapeutically active substance except a local anaesthetic or astringent.

HYDROGEN PEROXIDE except when included in Schedule 1

HYOSCINE, except hyoscine butylbromide when included in Schedule 2 or 3 –

(a) when in preparations containing 0.25 per cent or less of hyoscine; or
(b) in transdermal applicators containing 2 mg or less of hyoscine.

HYOSCINE BUTYLBROMIDE as the only therapeutically active ingredient in a pack containing 200mg or less of hyoscine butylbromide.
HYOSCYAMINE in preparations containing 0.25 per cent or less of hyoscyamine.
HYOSCYAMUS NIGER in preparations containing 0.25 per cent or less of the alkaloids of hyoscyamus calculated as hyoscyamine.
HYPROMELLOSE eye drops

IBUPROFEN when:
oral preparations of 200mg or less per dosage unit in pack size up to 30 dosage units; and
as a preparation for external use

IDOXURIDINE in preparations containing 0.5 per cent or less of idoxuridine for cutaneous use.
INDANAZOLINE

INDOMETHACIN when –
oral preparations of 25mg or less per dosage unit in pack size up to 30 dosage units; or
as a preparation for external use

INOSITOL NICOTINATE.
INSULIN
IODINE (excluding its salts, derivatives and iodophors), in preparations for human therapeutic use containing more than 2.5 per cent of available iodine.
IPRATROPIUM as a nasal spray.
IRON COMPOUNDS for human internal use with a recommended daily dose of 24mg of elemental iron or less.
ISOCONAZOLE for human use in dermal or vaginal preparations
ISOPROPAMIDE in preparations containing 2 per cent or less of isopropamide for cutaneous use.
ISOSORBIDE DINITRATE for therapeutic use.
IVERMECTIN for use in animals.
KETOCONAZOLE for human use as a preparation for dermal or vaginal use

KETOPROFEN when –

(a) oral preparations of 25mg or less per dosage unit in pack size up to 30 dosage units; and
as a preparation for external use containing 1% or less.

LACTULOSE in preparations for human therapeutic use.
LEVOCABASTINE in topical eye or nasal preparations.
LIQUID PARAFFIN preparations for internal use.
LITHIUM preparations for therapeutic dermal use containing 1 per cent or less of lithium except in preparations containing 0.01 per cent or less of lithium.
LOBELIA in preparations containing 0.5 per cent or less of lobeline, except in preparations for smoking or burning.
LOBELINE except for preparations for smoking or burning.
LODOXAMIDE in preparations for ophthalmic use.
LOPERAMIDE in packs of 8 dosage units or less, each dosage unit containing 2 mg or less of loperamide.
LORATADINE for oral use.
MACROGOL 3350 for bowel cleansing prior to diagnostic medical or surgical procedures.
MALDISON in preparations for external human therapeutic use except in preparations containing 2 per cent or less of maldison.
MANNITYL HEXANITRATE for therapeutic use.
MEBENDAZOLE in the treatment of animals.
MEFENAMIC ACID in packs of 30 or less dosage units for treatment of spasmodic dysmenorrhoea.
MERCURY ORGANIC COMPOUNDS for topical human therapeutic use, in preparations containing 0.5 per cent of less of mercury.
MEPYRAMINE in oral preparations.
METHDILAZINE in oral preparations.

METHOXAMINE except –

(a) preparations containing 0.5 per cent or less of methoxamine; or
(b) preparations for external use containing 1 per cent or less of methoxamine.

METHOXYPHENAMINE
METHYLEPHEDRINE
METOCLOPRAMIDE packaged and labelled for the treatment of nausea in packs containing not more than 10 dosage units and supplied under medical advice.
MICONAZOLE for human use in preparations for dermal or vaginal use.
MINOXIDIL in preparations for dermal use containing 5 per cent or less of minoxidil
MOMETSONE in aqueous nasal sprays for the prophylaxis or treatment of allergic rhinitis, for up to 6 months use.
MUCOPOLYSACCHARIDE for external use.
NAPHAZOLINE

NAPROXEN when –
(a) oral preparations of 275mg or less per dosage unit in pack size up to 30 dosage units; and
(b) as a preparation for external use containing 1% or less.

NICLOSAMIDE for human therapeutic use.
NICOTINE in patches, gums, inhalers and other products for the purpose of smoking cessation with appropriate counselling from pharmacist or druggist.

NICOTINIC ACID for human therapeutic use except
in preparations containing 100mg or less of nicotinic acid per dosage unit; or
nicotinamide

NICOTINYL ALCOHOL except in preparations containing 100mg or less of nicotinyl alcohol per dosage unit.
NIZATADINE for relief of symptoms of gastro-oesophageal reflux, in packs containing not more than 14 days supply.
NITRIC ESTERS of polyhydric alcohols for therapeutic use except when separately specified in these Schedules.
NITROFURAZONE in preparation for cutaneous use containing 0.2 per cent or less of nitrofurazone.
NOSCAPINE
NYSTATIN as oral drops, dermal and vaginal preparations.
OXETHAZAINE (oxetacaine) in preparations for internal use only.
OXYMETAZOLINE
PANCREASE preparations
PARACETAMOL except when included in Schedule 1 or 3.
PARADICHLOROBENZENE containing ear preparations.
PAPAVERINE
PARAFORMALDEHYDE for human therapeutic use except in preparations containing 5 per cent or less of paraformaldehyde.
PENCICLOVIR for topical use containing 5% or less of penciclovir.
PERMETHRIN in lice preparations.
PHEDRAZINE
PHENAMAZOLINE
PHENAZONE for external use.
PHENIRAMINE in oral preparations.
PHENOTHRIN in lice preparations.
PHENOXYMETHYLPENICILLIN for minor infections where a maximum of 7 days treatment may be supplied.

PHENYLEPHRINE except –

(a) when included in Schedule 3; or
(b) preparations containing 0.5 per cent or less of phenylephrine; or
(c) preparations for external use containing 1 per cent or less of phenylephrine.

PHENYLPROPANOLAMINE in preparations for relief of coughs or colds, containing 25 mg or less per dose of phenylpropanolamine.
PHENYLTOLOXAMINE in oral preparations.

PHOLCODINE, –

(a) when compounded with one or more other therapeutically active substances in divided preparations containing 10 mg or less of pholcodine per dosage unit and with a recommended dose not exceeding 25 mg of pholcodine; or

(b) in undivided preparations containing 0.5 per cent or less of pholcodine and with a recommended dose not exceeding 25 mg of pholcodine.

PHOSPHATE based enemas.
PHOSPHATE tablets for internal use.
PHYTOMENADIONE
PIPERAZINE preparations for oral use.
PODOPHYLLUM RESIN (Podophyllin) in preparations containing 20 per cent or less of podophyllin for external use on warts other than anogenital warts.
PODOPHYLLOTOXIN in preparations containing 1 per cent or less of podophyllin for external use on warts other than anogenital warts.
POLYETHYLENE GLYCOLS
POLYVINYL ALCOHOL eye preparation.
POTASSIUM BICARBONATE
POTASSIUM CHLORIDE preparations.
POTASSIUM CHLORATE for therapeutic use except in preparations containing 10 per cent or less.
POTASSIUM CITRATE mixture
POTASSIUM PERMANGANATE.
PRAMOXINE when included in preparations for external use, other than eye drops, containing 1 per cent or less of pramoxine.
PRILOCAINE in preparations for topical use other than eye drops, containing 10 per cent or less of total anaesthetic substances.
PROCHLORPERAZINE packaged and labelled for the treatment of nausea in packs containing not more than 10 dosage units.
PROCYCLIDINE in preparations containing 5 per cent or less of procyclidine for cutaneous use.
PROMETHAZINE in oral preparations.
PROPYL SALICYLATE for external use.
PROPYLENE GLYCOL for internal use.
PROPYLHEXEDRINE in appliances for inhalation in which the substance is absorbed upon an inert solid material.

PSEUDOEPHEDRINE, where the quantity supplied is not more than a reasonable amount for personal use and,

(a) in divided preparations containing 60 mg or less of pseudoephedrine per recommended dosage unit either as a single active agent or in combination with other therapeutically active agents; or
(b) in liquid preparations containing 60 mg or less of pseudoephedrine per recommended adult dose either as a single active agent or in combination with other therapeutically active agents

PULVERIZED MAIZE
PYRANTEL for human therapeutic use.
QUININE for human internal therapeutic use for the treatment of cramps except in liquids containing 40 mg/L or less of quinine.
RANITIDINE for relief of symptoms of gastro-oesophageal reflux, in packs containing not more than 14 days supply.
RESORCINOL containing preparations.
SULFACETAMIDE for preparations for ophthalmic with 10% or less of sulfacetamide.

SALBUTAMOL

(a) in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or
(b) in capsules of dry powder for inhalation delivering 200 micrograms or less of salbutamol per dose.

SALICYLIC ACID for dermal use containing more than 40% salicylic acid.
SALICYLAMIDE except when included in Schedule 1 or 3.
SANTONIN
SELENIUM SULPHIDE for external use.
SILVER for therapeutic use except in preparations containing 1 per cent or less of silver.
SIMETHICONE in infant colic drops.
SOAP SPIRIT
SODIUM CITRATE based enemas.
SODIUM CROMOGLYCATE in nasal preparations or eye drops.
SODIUM LACTATE for external use.
SODIUM LAURYL SULPHATE
SODIUM NITRITE for therapeutic use ( excluding when included as an excipient)
SODIUM PHOSPHATE in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures.
SODIUM PICOSULFATE in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures.
SORBIC ACID
SORBITOL in preparations for human therapeutic use.
SQUILL except in preparations containing 1 per cent or less of squill.
STRAMONIUM in preparations containing 0.25 per cent or less of the alkaloids calculated as hyoscyamine, except preparations for smoking or burning.
SULCONAZOLE in preparations for dermal use.
SULFACETAMIDE in preparations for ophthalmic use containing 10 per cent or less of sulfacetamide.
SULFACONAZOLE in dermal use.
SULFADOXINE with PYRIMETHAMINE 500mg/25mg (Fansidar™) tablet for treatment of malaria when required according to current standard practice.
TERBINAFINE in preparations for dermal use.
TERBUTALINE in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose.
TETRACHLOROETHYLENE for human therapeutic use.
TETRACYCLINE eye ointment for use in infectious conjunctivitis.
TETRAHYDROZOLINE
THIABENDAZOLE in the treatment of animals.
THENYLDIAMINE in oral preparations.
THEOPHYLLINE in liquid oral preparations containing 2 per cent or less of theophylline
THYMOL
TIOCONAZOLE for human in preparations for dermal or vaginal use.
TRAMAZOLINE
TRANEXAMIC ACID for treatment of menorrhagia.
TRIAMCINOLONE ACETONIDE for treatment of mouth ulcers and nasal sprays only.
TRICLOSAN

TRIMEPRAZINE

(a) in solid oral preparations; or
(b) in liquid oral preparations containing 10 mg or less of trimeprazine
per 5 ml.

TRIPROLIDINE in oral preparations.
TUAMINOHEPTANE.
TYMAZOLINE
UREA HYDROGEN PEROXIDE or CARBAMIDE PEROXIDE ear drops
VITAMIN A for human therapeutic use except when included in Schedule 1or 3.
XYLOMETAZOLINE
ZINC CHLORIDE for human dermal use except in preparations containing 5 per cent or less of zinc chloride.
ZINC SULPHATE eye drops.

ZINC COMPOUNDS for human internal use:
in preparations with a recommended daily dose of 25mg or less of zinc; or
in preparations with a recommended daily dose of more than 25mg but not more than 50mg of zinc when labeled with a warning statement that it is dangerous to take a large amount of zinc for a long period of time.

SCHEDULE 3

(Substances marked # require special authorization from the Principal Pharmacist)

ABACAVIR
ABCIXIMAB
ACAMPROSATE CALCIUM
ACARBOSE
ACEBUTOLOL
ACEPIFYLLINE except when included in Schedule 2.
ACEPROMAZINE
ACETANILIDE and alkyl acetanilides, for human therapeutic use.
ACETARSOL
ACETAZOLAMIDE
ACETOHEXAMIDE
ACETYLCARBROMAL
ACETYLCHOLINE and other choline esters except when separately specified in this Schedule.
ACETYLCYSTEINE except when included in Schedule 2.
ACETYLDIGITOXIN

ACETYL-DIHYDROCODEINE, when compounded with one or more other medicaments –
(a) in divided preparations containing not more than 100 mg of acetyldihydrocodeine per dosage unit; or
(b) in undivided preparations with a concentration of not more than 2.5 per cent of acetyldihydrocodeine.

ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE
ACETYLSTROPHANTHIDIN
ACICLOVIR expect when included in Schedule 2
ACIPIMOX
# ACITRETIN
ACOKANTHERA OUABAIO
ACOKANTHERA SCHIMPERI
ACONITUM
ACTINOMYCIN D
#ADAPALENE
ADENOSINE
ADIPHENINE
ADONIS VERNALIS

ADRENALINE except –
(a) when included in Schedule 2; or
(b) in preparations containing 0.02 per cent or less of adrenaline.

ADRENOCORTICAL HORMONES except when separately specified in these Schedules.
AGALSIDASE ALFA
AGALSIDASE BETA
AGLEPRISTONE
ALATROFLOXACIN MESYLATE
ALBENDAZOLE except when included in Schedule 2
ALCLOFENAC
ALCLOMETASONE except when included in Schedule 2
ALCURONIUM SALTS
ALDESLEUKIN
ALDOSTERONE
ALEFACEPT
ALENDRONATE SODIUM
ALENDRONIC ACID
ALFACALCIDOL
ALFUZOSIN
ALGLUCERASE
ALLERGENS
ALLOPURINOL
ALLYLOESTRENOL
ALOSETRON
alpha-CHLORALOSE – See chloralose
ALPHADOLONE
ALPHAXALONE
ALPRAZOLAM
ALPRENOLOL
ALPROSTADIL
ALSEROXYLON
ALTEPLASE
ALTRENOGEST
ALTRETAMINE (hexamethylmelamine)
AMANTADINE
AMBENONIUM
AMBUCETAMIDE
AMBUTONIUM
AMCINONIDE
AMETHOCAINE except when included in Schedule 2
AMIFOSTINE
AMIKACIN
AMILORIDE
3-AMINOBENZOIC ACID ETHYL ESTER METHANESULPHONATE
AMINOCAPROIC ACID
AMINOGLUTETHIMIDE
AMINOMETRADINE
AMINOPHENAZONE and derivatives therefrom for the treatment of animals.
AMINOPHYLLINE except when included in Schedule 2.
AMINOPTERIN
4-AMINOPYRIDINE for therapeutic use.
AMINOREX
AMINOSALICYCLIC ACID
AMIODARONE
AMIPHENAZOLE
AMISOMETRADINE
AMISULPRIDE
AMITRIPTYLINE and other compounds structurally derived therefrom by substitution in the side chain except when separately specified in this Schedule.
AMLODIPINE
AMMI VISNAGA
AMMONIA BROMIDE for therapeutic use.
AMODIAQUINE
AMOROLFINE except when included in Schedule 2.
AMOXAPINE
AMOXYCILLIN
AMPHOMYCIN
AMPHOTERICIN
AMPICILLIN
AMPRENAVIR
AMRINONE
AMSACRINE
AMYL NITRITE
AMYLOBARBITONE when packed and labelled for injection.
AMYLOCAINE
# ANABOLIC STEROIDAL AGENTS except when separately specified in this Schedule.
ANAGRELIDE
ANAKINRA
ANASTROZOLE
ANCESTIM
ANCROD and its immunoglobulin antidote
# ANDROGENIC STEROIDAL AGENTS.
# ANDROISOXAZOLE
# ANDROSTANOLONE
# ANDROSTENEDIOL
# ANDROSTENEDIONE
ANGIOTENSINAMIDE
ANISTREPLASE
ANTAZOLINE except when included in Schedule 2.

ANTIBIOTICS except
(a) when separately specified in these Schedules; or
(b) avoparcin when packed and labelled for use as an animal feed additive; or
(c) nisin.

ANTIGENS for human therapeutic use except when separately specified in this Schedule.

ANTIHISTAMINES except
(a) when included in Schedule 1 or 2; or
(b) when separately specified in this Schedule.

ANTIMALARIAL SUBSTANCES except when separately specified in this Schedule.
ANTIMONY, organic compounds of, for therapeutic use.
ANTISERA (immunosera) for human use by injection except when separately specified in these Schedules.
ANTITUBERCULAR SUBSTANCES including isoniazid and its derivatives, para-aminosalicyclic acid and thiacetazone except when separately specified in these Schedules.
APOCYNUM spp.
APOMORPHINE
APRACLONIDINE
APRAMYCIN
APREPITANT
APRONAL
APROTININ
APRECOLINE
ARSENIC - See THIACETARSAMIDE
ARIPIPRAZOLE
ARTEMETHER
ASPIDOSPERMA QUEBRACHO
ASPIRIN when combined with caffeine, paracetamol or salicylamide or any derivative of these substances.
ASTEMIZOLE
# ATAMESTANE
ATAZANAVIR
ATENOLOL
ATIPAMEZOLE
ATOMOXETINE
ATORVASTATIN
ATOVAQUONE
ATRACURIUM BESYLATE
ATROPA BELLADONNA (belladonna) except when included in Schedule 2.
ATROPINE METHONITRATE
ATROPINE except when included in schedule 2.
AURANOFIN
AUROTHIOMALATE SODIUM

AVILAMYCIN except
in animal feed premixes containing 15 per cent or less of avilamycin activity ; or
in animal feeds containing 15 mg/kg or less of avilamycin activity.

AVIPTADIL
AVOPARCIN
AZACYCLONOL
AZAPERONE
AZAPETINE
AZAPROPAZONE
AZARIBINE
AZATADINE except when included in Schedule 2.
AZATHIOPRINE
AZELAIC ACID except when included in Schedule 2.
AZELASTINE except when included in Schedule 2.
AZITHROMYCIN
AZLOCILLIN
AZTREONAM
BACAMPICILLIN

BACITRACIN except
(a) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances; or
(b) in milk replacers for calves and starter rations for pigs, containing 100 mg/kg or less of antibiotic substances.

BACLOFEN
BALSALAZIDE
BAMBUTEROL
BAMETHAN
BAMIPINE
BARBITURIC ACID and its derivatives except when separately specified in this Schedule.
BASILIXIMAB
BECAPLERMIN
BECLAMIDE
BECLOMETHASONE except when included in Schedule 2.
BEMEGRIDE
BENACTYZINE and other substances structurally derived from diphenylmethane with ataractic properties when used for therapeutic purposes.
BENAZEPRIL
BENDROFLUAZIDE
BENETHAMINE PENICILLIN.
BENORYLATE
BENOXAPROFEN.
BENPERIDOL
BENSERAZIDE

BENZAMINE, except when included in Schedule 1.

BENZATHINE PENICILLIN
BENZHEXOL
BENZILONIUM

BENZOCAINE, except when included in Schedule 1.
BENZODIAZEPINE derivatives except when separately specified in these Schedules.

BENZOYL PEROXIDE in preparations for external human therapeutic use, except when included in Schedule 1 or 2.
BENZPHETAMINE
BENZTHIAZIDE
BENZTROPINE

BENZYDAMINE except when included in Schedule 1.

BENZYLPENICILLIN (including procaine penicillin).
BEPRIDIL
BERACTANT
BETAHISTINE
BETAMETHASONE
BETAXOLOL
BETHANECHOL CHLORIDE
BETHANIDINE
BEVANTOLOL
# BEXAROTENE
BEZAFIBRATE
BICALUTAMIDE
BIFONAZOLE except when included in Schedule 2.
BIMATOPROST
BIPERIDEN

BISMUTH compounds of, for human therapeutic or cosmetic use, except –
(a) bismuth citrate when incorporated in hair colourant preparations

in concentrations of 0.5 per cent or less; or
(b) bismuth oxychloride in cosmetics; or
(c) bismuth formic iodide or bismuth subiodide in dusting powders

containing 3 per cent or less of bismuth.

BISOPROLOL
BIVALIRUDIN
BLEOMYCIN
# BOLANDIN
# BOLASTERONE
# BOLAZINE
# BOLDENONE (dehydrotestosterone)
# BOLENOL
# BOLMANTALATE

BORON for human therapeutic use –
(a) for internal use; or
(b) in glycerines or honeys of borax or boric acid; or
(c) in dusting powders for paediatric use; or
(d) as a therapeutically active ingredient in other preparations for dermal use except -
(i) in antifungal preparations; or
(ii) in preparations containing 0. 1 per cent or less of boron.

# BOSENTAN
BOTULINUM TOXINS for human use except when separately specified in the Schedules.
BRETYLIUM TOSYLATE
BRIMONIDINE
BRINZOLAMIDE
BROMAZEPAM
BROMIDES, inorganic, for therapeutic use.
BROMOCRIPTINE
BROMOFORM for therapeutic use.
BROMPHENIRAMINE except when included in Schedule 2.
BROMVALETONE
BRUGMANSIA spp
BUCLIZINE except when included in Schedule 2.
BUDESONIDE except when included in Schedule 2.
BUFEXAMAC except in preparations containing 5 per cent or less of bufexamac for external human therapeutic use, including suppositories.
BUMETANIDE
BUPHENINE
BUPIVACAINE
BUPROPION
BUSERELIN
BUSPIRONE
BUSULPHAN
BUTACAINE

BUTYLAMINOBENZOATE except when included in Schedule 1.

BUTYLCHLORAL HYDRATE
BUTYL NITRATE
CABERGOLINE
CALCIPOTRIOL
CALCITONIN
CALCITRIOL
CALCIUM CARBIMIDE for therapeutic use.
CALCIUM POLYSTYRENE SULPHONATE
CALOTROPIS GIGANTEAN
CALOTROPIS PROCERA
# CALUSTERONE
CAMPHORATED OIL excluding admixtures.
CAMPHOTAMIDE
CANDESARTEN CILEXETIL
CANDICIDIN
CANINE TICK ANTI-SERUM
CANTHARIDIN
CAPECITABINE
CAPREOMYCIN
CAPTODIAME
CAPTOPRIL
CAPURIDE
CARAMIPHEN
CARBACHOL
CARBAMAZEPINE
CARBARYL for human therapeutic use except when included in Schedule 2.
CARBAZOCHROME
CARBENICILLIN
CARBENOXOLONE except when included in Schedule 2.
CARBIDOPA
CARBIMAZOLE
CARBOCROMEN
CARBOPLATIN
CARBOPROST
CARBROMAL
CARDIAC GLYCOSIDES except when separately specified in these Schedules.
CARBUTAMIDE
CARINDACILLIN
CARISOPRODOL
CARMUSTINE
CARNIDAZOLE
CARPROFEN
CARVEDILOL
CASPOFUNGIN
CEFACLOR
CEFEPIME
CEFETAMET
CEFIXIME
CEFODIZIME
CEFONICID
CEFOPERAZONE
CEFOTAXIME
CEFOTETAN
CEFOTIAM
CEFOXITIN
CEFPIROME
CEFPODOXIME
CEFSULODIN
CEFTAZIDIME
CEFTIBUTEN
CEFTIOFUR
CEFTRIAXONE
CEFUROXIME
CELECOXIB
CELIPROLOL
CEPHACETRILE
CEPHADROXIL for the treatment of animals.
CEPHAELIS ACUMINATA (ipecacuanha) except in preparations containing 0.2 per cent or less of emetine.
CEPHALEXIN
CEPHALONIUM
CEPHALORIDINE
CEPHALOTHIN
CEPHAMANDOLE
CEPHAPIRIN
CEPHAZOLIN
CEPHRADINE
CERIVASTATIN
CERULETIDE
CETIRIZINE except when included in Schedule 2.
CETRORELIX
CHENODEOXYCHOLIC ACID
CHLORAL FORMAMIDE

CHLORAL HYDRATE except –
(a) when included in Schedule 2; or
(b) in preparations for topical use containing 2 per cent or less of chloral hydrate.

CHLORALOSE
CHLORAMBUCIL
CHLORAMPHENICOL
# CHLORANDOSTENOLONE
CHLORAZANIL
CHLORBUTOL in preparations for human oral use, except when included in Schedule 2.
CHLORCYCLIZINE
CHLORDIAZEPOXIDE
CHLORMERODRIN
CHLORMETHIAZOLE
CHLORMEZANONE
CHLOROFORM for the use in anaesthesia.
4-CHLOROMETHANDIENONE
2-(4-CHLOROPHENYL)-1,2,4-TRIAZOLE [5,1a]-ISOQUINOLINE for the treatment of animals.
CHLOROQUINE except when included in Schedule 2.
CHLOROTHIAZIDE
CHLOROTRIANISENE
# CHLOROXYDIENONE
CHLORPHENIRAMINE except when included in Schedule 2.
CHLORPHENTERMINE
CHLORPROMAZINE
CHLORPROPAMIDE
CHLORPROTHIXENE
CHLORQUINALDOL for human topical use.
CHLORTETRACYCLINE
CHLORTHALIDONE
CHLORZOXAZONE
CHOLERA VACCINE
CHOLESTYRAMINE for human therapeutic use.
CHYMOPAPAIN, injection for human therapeutic use.
CICLACILLIN
CICLESONIDE
CICLOPIROX except when included in Schedule 2.
CODOFOVIR
CILASTATIN
CILAZAPRIL
CIMETIDINE except when included in Schedule 2.
CINCHOCAINE except when included in Schedule 2.
CINOXACIN
CIPROFLOXACIN
CISAPRIDE
CISATRACURIUM BESYLATE
CISPLATIN
CITALOPRAM
CLADRIBINE
CLANOBUTIN, in injections for the treatment of animals.
CLARITHROMYCIN
CLAVULANIC ACID
CLEMASTINE except when included in Schedule 2.
CLEMIZOLE
CLENBUTEROL
CLIDINIUM
CLINDAMYCIN
CLIOQUINOL and other halogenated derivatives of 8-Hydroxyquinoline for external human use.
CLOBAZAM
CLOBETASOL
CLOBETASONE-17-BUTYRATE except when included in Schedule 2.
CLOCORTOLONE
CLODRONIC ACID (included sodium clodronate)
CLOFAZIMINE
CLOFENAMIDE
CLOFIBRATE
# CLOMIPHENE
CLOMIPRAMINE
CLOMOCYCLINE
CLONAZEPAM
CLONIDINE
CLOPAMIDE
CLOPIDOGREL
CLOPROSTENOL
CLORAZEPATE
CLOREXOLONE
CLORPRENALINE
# CLOSTEBOL (4-chlorotestosterone).
CLOTRIMAZOLE, except when included in Schedule 2.
CLOXACILLIN
# CLOZAPINE under regular monitoring by the doctor.

CODEINE when compounded with therapeutically active substances –
(a) in divided preparations containing 30 mg or less of codeine per dosage unit;
(b) in undivided preparations containing 1 per cent or less of codeine.except when included in Schedules 1or 2,

CO-DERGOCRINE
COLASPASE
COLCHICINE
COLCHICUM AUTUMNALE
COLESTIPOL for human therapeutic use.
COLFOSCERIL PALMITATE for therapeutic use.
COLISTIN
COLLAGEN in injection or implantation for human use
CONVALLARIA MAJALIS.
COPPER COMPOUNDS for human use except when separately specified in these Schedules
CORONILLA spp.
CORTISONE and steroid suprarenal cortical hormones, except hydrocortisone in Schedule 2.
CORTICOTROPHIN
COUMARIN
CRYSTAL VIOLET
CUPRIMYXIN
CURARE, TUBOCURARINE , d-TUBOCURARINE, d-TUBOCURARINEDIMETHYLETHER and all synthetic quaternary
ammonium compounds and other compounds having curarising properties except when separately specified in this Schedule.
CYCLANDELATE
CYCLIZINE
CYCLOBENZAPRINE
# CYCLOFENIL
CYCLOHEXIMIDE
CYCLOPENTHIAZIDE
CYCLOPENTOLATE
CYCLOPHOSPHAMIDE
CYCLOPROPANE for therapeutic use.
CYCLOSERINE
CYCLOSPORIN
CYCLOTHIAZIDE
CYCRIMINE
CYMARIN
CYPROHEPTADINE except when included in Schedule 2.
CYPROTERONE
CYSTEAMINE
CYTARABINE
DACARBAZINE
DACLIZUMAB
DALFOPRISTIN
DALTEPARIN
DANAPAROID
# DANAZOL
DANTHRON
DANTROLENE
DAPSONE and all derivatives of 4,4-diaminodiphenylsulphone.
# DARBEPEOTIN ALFA.
DATURA spp except when included in Schedule 2 or separately specified in this schedule.
DATURA stramonium except when included in Schedule 2 or separately specified in this schedule.
DATURA tatula except when included in Schedule 2 or separately specified in this schedule.
DAUNORUBICIN
DEANOL
DEBRISOQUINE
DECAMETHONIUM SALTS.
DEFERIPRONE
DEFLAZACORT
# DEHYDROCHLOROMETHYLTESTOSTERONE
DIHYDROCORTICOSTERONE
DELAVIRIDINE
DEMBREXINE except when included in Schedule 1.
DEMECARIUM BROMIDE
DEMECLOCYCLINE
DEOXYCORTONE
DEOXYRIBONUCLEASE except for external use or when separately specified in these schedule.
DESFERRIOXAMINE
DESFLURANE
DESIPRAMINE
DESIRUDIN
DESLANOSIDE
DESLORATADINE except when included in Schedule 2
DESLORELIN
DESMOPRESSIN (D.D.A.V.P.)
DESOGESTREL
DESONIDE
DEOXYMETHASONE
DETOMIDINE
DEXAMETHASONE
DEXCHLORPHENIRAMINE except when included in Schedule 2.
DEXFENFLURAMINE
DEXMEDETOMIDINE
DEXTROMETHORPHAN except when included in Schedule 2

DEXTROPROPOXYPHENE –
(a) in divided preparations containing 135 mg of dextropropoxyphene or less per dosage unit, or
(b) liquid preparations containing 2.5 per cent or less of dextropropoxyphene.

DEXTRORPHAN
DIAMTHAZOLE
DIAZEPAM
DIAZOXIDE
DIBENZEPIN
trans-4-((3,5-DIBROMO-2-HYDROXYBENZYL)-AMINO) CYCLOHEXANOL HYDROCHLORIDE MONOHYDRATE (Sputolysin) except when included in Schedule 1.
DICHLORALPHENAZONE
DICHLORPHENAMIDE
DICLOFENAC except when included in Schedule 2.
DICLOXACILLIN
DICYCLOMINE except when included in Schedule 2.
DIDANOSINE
DIENOESTROL
DIENOGEST
DIETHAZINE
DIETHYLCARBAMAZINE for human therapeutic use.
#DIETHYLPROPION
DIFENOXIN in preparations containing, per dosage unit, 0.5 mg or less of difenoxin and a quantity of atropine sulphate equivalent to at least 5 per cent of the dose of difenoxin.
DIFLORASONE
DIFLOXACIN
DIFLUCORTOLONE
DIFLUNISAL
DIGITALIS and its glycosides.
DIGITOXIN
DIGOXIN
DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F (Ab).
DIHYDRALAZINE

DIHYDROCODEINE when compounded with one or more other medicaments –
(a) in divided preparations containing not more than 100 mg

of dihydrocodeine per dosage unit; or
(b) in undivided preparations with a concentration of not more than 2.5

per cent of dihydrocodeine,

except when included in Schedule 2

DIHYDROERGOTOXINE
# DIHYROLONE
DIHYDROSTREPTOMYCIN
DI-IODOHYDROXYQUINOLINE except when included in Schedule 2.
DIISOPROPYLAMINE DICHLOROACETATE
DILTIAZEM
DIMENHYDRINATE except when included in Schedule 2.
DIMERCAPROL
# DIMETHANDROSTANOLONE
# DIMETHAZINE
DIMETHINDENE except when included in Schedule 2.
DIMETHOXANATE

DIMETHYL SULFOXIDE for therapeutic use except when –
included in Schedule 1; or
in in-vitro test kits.

DIMETRIDAZOLE
DIMETHISOQUIN
DINIETHOXANATE
2,4-DINITROCHLOROBENZENE for therapeutic use
DINITROCRESOLS for therapeutic use.
DINITRONAPHTHOLS for therapeutic use.
DINITROPHENOLS for therapeutic use.
DINITROTHYMOLS for therapeutic use.
# DINOPROST
# DINOPROSTONE
DIPERODON
DIPHEMANIL METHYLSULPHATE except when included in Schedule 1.
DIPHENHYDRAMINE except when included in Schedule 2.
DIPHENIDOL
DIPHENOXYLATE except when included in Schedule 2.
DIPHENYLPYRALINE except when included in Schedule 2.
DIPTHERIA TOXOID
DIPIVEFRIN
DIPYRIDAMOLE
DIRITHROMYCIN
DISOPHENOL
DISPYRAMIDE
DISTIGMINE
DISULFIRAM for therapeutic use.
DISULPHAMIDE
DITHIAZANINE
DITIOCARB
DOBUTAMINE
DOCETAXEL
DOFETILIDE
DOLASETRON
DOMPERIDONE
DONEPEZIL
DOPAMINE
DOPEXAMINE
DORNASE
DORZOLAMIDE
DOTHIEPIN
DOXANTRAZOLE
DOXAPRAM
DOXAZOSIN
DOXEPIN
DOXORUBICIN
DOXYCYCLINE
DOXYLAMINE except when included in Schedule 2.
DROSPIRENONE
DROPERIDOL
# DROSTANOLONE
DROTRECOGIN ALFA
DUBOISIA LEICHHARDTII except when included in Schedule 2.
DUBOISIA MYOPOROIDES except when included in Schedule 2.
DUTASERIDE
DYDROGESTERONE
ECONAZOLE except when included in Schedule 2.
ECOTHIOPATE
ECTYLUREA
EDETIC ACID for human therapeutic use in preparations for injection or infusion.
EDOXUDINE
EDROPHONIUM SALTS.
EFAVIRENZ
EFLORNITHINE
EFORMOTEROL (formoterol)
ELETRIPTAN
ELTENAC
EMEPRONIUM SALTS.
EMETINE except in preparations containing 0.2 per cent or less of emetine.
ENALAPRIL
# ENESTEBOL.
ENFLURANE for therapeutic use.
ENOXACIN.
ENOXAPARIN.
ENOXIMONE
ENPROSTIL
ENROFLOXACIN
ENTACAPONE
EPHEDRA spp except in preparations containing 0.001 per cent or less of ephedrine

EPHEDRINE when
in preparations for topical use containing 1 per cent or less of ephedrine; or
(b) compounded with one or more other therapeutically active substances in liquid preparations for internal use containing 10 mg or less of ephedrine per recommended dose, other than preparations for stimulant, appetite suppression or weight control purposes.
except when included in Schedule 2.

EPICILLIN
EPIRUBICIN
# EPITIOSTANOL
# EPOETIN ALFA
# EPOETIN BETA
EPOPROSTENOL
EPROSARTEN MESYLATE
EPTIFIBATIDE
ERGOMETRINE
ERGOT
ERGOTAMINE
ERGOTOXINE
ERTAPENEM
ERYSIMUM spp

ERYTHROMYCIN except –
(a) in animal feeds for growth promotion containing 50 mg/kg or less

of antibiotic substances; or
(b) in milk replacers for calves or starter rations for pigs, containing 100 mg/kg or less of antibiotic substances.

ERYTHROPOIETIN
ERYTHROPOIETINS except when separately specified in these Schedules.
ESMOLOL
ESOMEPRAZOLE
ESTRAMUSTINE
ESTROPIPATE (piperazine oestrone sulfate).
ETANERCEPT
ETHACRYNIC ACID
ETHAMBUTOL
ETHAMIVAN
ETHANOLAMINE in preparations for injection.
ETHCHLORVYNOL
ETHER for use in anaesthesia.
ETHINAMATE
ETHINYLOESTRADIOL
ETHISTERONE
ETHOGLUCID
ETHOHEPTAZINE
ETHOPROPAZINE
ETHOSUXIMIDE
ETHOTOIN
ETHOXZOLAMIDE
ETHYL CHLORIDE for inhalation anaesthesia.
# ETHYLDIENOLONE

ETHYLMORPHINE when compounded with one or more other medicaments –
(a) in divided preparations containing not more than 100 mg of ethylmorphine per dosage unit; or
(b) in undivided preparations with a concentration of not more than 2.5 per cent of ethylmorphine.
except when included in Schedule 2

# ETHYLOESTRENOL
ETHYNODIOL
ETIDOCAINE
ETIDRONATE except in toothpastes and gels containing 1 per cent or less of etidronate.
ETILEFRIN HYDROCHLORIDE
ETIPROSTON
ETODOLAC
ETOFENAMATE except when included in Schedule 2.
ETONOGESTREL
ETOPOSIDE
ETORICOXIB

# ETRETINATE –(The prescriber must, where the patient is a woman of child-bearing age:
ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and
advise the patient to avoid becoming pregnant during or for a period of one month after completion of treatment.)

EXEMESTANE
EZETIMIBE
FAMOTIDINE except when included in Schedule 2.
FELBINAC except when included in Schedule 2.
FELODIPINE
FELYPRESSIN
FENBUFEN
FENCAMFAMIN
FENCLOFENAC
FENFLURAMINE
FENOFIBRATE
FENOLDOPAM
FENOPROFEN
FENOTEROL except when included in Schedule 2.
FENPIPRAMIDE
FENPIPRANE
FENPROPOREX
FENPROSTALENE
FEXOFENADINE except when included in Schedule 2.
FIBRINOLYSIN
FILGRASTIM
FINASTERIDE
FIROCOXIB
FLAVOPHOSPHOLIPOL (bambermycin) except - in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.
FLECAINIDE
FLEROXACIN
FLOCTAFENINE
FLORIFENICOL
FLUANISONE
FLUCLOROLONE
FLUCLOXACILLIN
FLUCONAZOLE
FLUCYTOSINE
FLUDARABINE
FLUDROCORTISONE
FLUFENAMIC ACID
FLUMAZENIL
FLUMETHASONE
FLUMETHIAZIDE
FLUNISOLIDE except when included in Schedule 2.
FLUNIXIN MEGLUMINE for the treatment of animals.
FLUOCINONIDE
FLUOCORTIN
FLUOCORTOLONE
FLUORIDES in preparations for human ingestion except when included in Schedule 2.
FLUORESCEIN
FLUOROMETHOLONE
FLUOROURACIL and other substances structurally derived from uracil with cytotoxic properties when used for therapeutic purposes.
FLUOXETINE.
# FLUOXYMESTERONE
FLUPENTHIXOL
FLUPHENAZINE
FLUPROSTENOL
FLURANDRENOLONE
FLURAZEPAM
FLURIBIPROFEN except when included in Schedule 2.
FLUROXENE for inhalation anaesthesia.
FLUSPIRILENE
FLUTAMIDE
FLUTICASONE except when included in Schedule 2.
FLUVASTATIN
FLUVOXAMINE
FOLIC ACID in preparations for injections.
FOLINIC ACID in preparations for injections.
# FOLLICLE STIMULATING HORMONE (See also gonadotrophins)
# FOLLITROPIN ALPHA
# FOLLITROPIN BETA
FOMVIRSEN
FONDAPARINUX
# FORMEBOLONE
FORMESTANE
FOSCARNET
FOSFETROL
FOSINOPRIL
FOSPHENYTOIN SODIUM
FOTEMUSTINE
FRAMYCETIN
FRUSEMIDE
FURALTADONE
# FURAZABOL
FURAZOLIDONE
FUSIDIC ACID
GABAPENTIN
GALANTHAMINE
GALANTHUS spp.
GALLAMINE.
GANCICLOVIR.
GANIRELIX.
GATIFLOXACIN.
GEFITINIB.
GEMCITABINE.
GEMEPROST.
GEMFIBROZIL.
GENTAMCIN.
GESTODENE.
GESTONORONE.
GESTRINONE.
GITALIN.
GLATIRAMER ACETATE.
GLIBENCLAMIDE.
GLIBORNURIDE.
GLICLAZIDE.
GLIMEPIRIDE.
GLIPIZIDE.
GLISOXEPRIDE.
GLUTATHIONE for parenteral use.
GLYCERYL TRINITRATE in preparations for injection or transdermal preparations for angina.
GLYCOPYRROLATE in preparations for injection.
GLYMIDINE
GONADORELIN
GONADOTROPHINS.
GOSERELIN ACETATE
GRAMICIDIN
GRANISETRON
GREPAFLOXACIN
GRISEOFULVIN
GUAIPHENESIN except when included in Schedule 1.
GUANABENZ
GUANACLINE
GUANETHIDINE
GUANIDINE
HACHIMYCIN
HAEMATIN
HAEMOPHILUS INFLUENZAE VACCINE
HALCINONIDE
HALOFANTRINE
HALOFENATE
HALOPERIDOL and other substances structurally derived from butyrophenone with ataractic properties when used for therapeutic purposes, except when separately specified in this Schedule.
HALOTHANE for therapeutic use.
HEMEROCALLIS
HEPARIN for internal therapeutic use.
HEPATITIS A VACCINE
HEPATITIS B VACCINE
HETACILLIN

HEXACHLOROPHANE –
(a) in preparations for use on infants; or
(b) in other preparations except when included in schedule 1.

HEXAMETHONIUM BROMIDE
HEXETIDINE
HEXOBENDINE
HEXOCYCLIUM
HISTAMINE except for therapeutic use except in preparations containing 0.5 per cent or less of histamine.
HOMATROPINE except when included in Schedule 2.
HUMAN CHORIONIC GONADATROPHIN except when included in Schedule 2.
HYALURONIDASE
HYALURONIC ACID in preparations for injection.
HYDRALAZINE
HYDRARGAPHEN for internal use.
HYDROCHLOROTHIAZIDE
HYDROCORTISONE except when included in schedule 2.
HYDROCYANIC ACID and CYANIDES in preparations for therapeutic use containing the equivalent of 0.15 per cent or less of hydrocyanic acid.
HYDROFLUMETHIAZIDE
HYDROQUINONE for human therapeutic use except in preparations containing 2 per cent or less of hydroquinone.
HYDROXYCHLOROQUINE
HYDROXYCOBALAMIN as a preparation for injection.
HYDROXYEPHEDRINE
HYDROXYPHENAMATE
HYDROXYPROGESTERONE
# HYDROXYSTENOZOL
1-HYDROXYPYRIDO (3,2,a)-5-PHENOXAZONE-3-CARBOXYLIC ACID
HYDROXYUREA
HYDROXYZINE
HYGROMYCIN except – in preparations in concentrations of 50 mg/kg or less of antibiotic substances.
HYOSCINE BUTYLBROMIDE except when included in Schedule 2.
HYOSCINE except when included in Schedule 2.
HYPROMELLOSE in preparations for injection.
HYOSCYAMINE except when included in Schedule 2.
HYOSCYAMUS NIGER except when included in Schedule 2.
HYPOTHALAMIC RELEASING FACTORS except when separately specified in this Schedule.
IBANDRONIC ACID
IBUFENAC
IBUPROFEN except when included in Schedule 2.
IBUTEROL
IBUTILIDE
IDARUBICIN
IDOXURIDINE except when included in Schedule 2.
IFOSFAMIDE
ILOPROST
IMATINIB
IMIGLUCERASE
IMIPENEM
IMIPRAMINE
IMIQUINOD
IMMUNOGLOBULINS for human parental use except when separately specified in these Schedules.
INDAPAMIDE
INDINAVIR
INDOMETHACIN except when included in Schedule 2.
INDOPROFEN
INDORAMIN
INFLIXIMAB
INFLUENZA AND CORYZA VACCINES
# INSULIN LIKE GROWTH FACTOR except when separately specified in these Schedules.
INTERFERONS
INTERLEUKINS except when separately specified in these Schedules.
IODOTHIOURACIL
ION-EXCHANGE RESINS, anionic and cationic, for internal use in humans except when separately specified in this Schedule.
IOPAMIDOL
IPRATROPIUM except when included in Schedule 2.
IPRIFLAVINE
IPRINDOLE
IPRONIAZID
IRON compounds in injectable preparations for human therapeutic use.
ISOAMINILE
ISOAMYL NITRITE
ISOBUTYL NITRITE
ISOCARBOXAZID
ISOCONAZOLE except when included in Schedule 2.
ISOETARINE
ISOFLURANE
ISOMETHEPTENE
ISONIAZID
ISOPRENALINE
ISOPRENALINE
ISOPRINOSINE
ISOPROPAMIDE except when included in Schedule 2
ISOSORBIDE DINITRATE except when included in Schedule 2
ISOSORBIDE MONONITRATE

# ISOTRETINOIN The prescriber must, where the patient is a woman of child-bearing age:
(a) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and
(b) advise the patient to avoid becoming pregnant during or for a period of one month after completion of treatment.

ISOXICAM
ISOXSUPRINE
ISRADIPINE
IVERMECTIN for human therapeutic use or treatment of mange is dogs.
KANAMYCIN
KETAMINE
KETANSERIN except in topical veterinary products containing 0.5 per cent or less of ketanserin.
KETAZOLAM
KETOCONAZOLE except when included in Schedule 2.
KETOPROFEN except when included in Schedule 2.
KETOROLAC
KETOTIFEN
KHELLIN
KITASAMYCIN except –in animal feeds for growth promotion containing 100 mg/kg or less of antibiotic substances.
LABETALOL
LACIDIPINE
LAMIVUDINE
LAMOTRIGINE
LANATOCIDE C
LANREOTIDE
LANSOPRAZOLE
LATAMOXEF
LATANOPROST
LAUDEXIUM METHYLSULPHATE
LAURETH-9 in preparations for injection.
LAUROMACROGOLS in preparations for injections except when separately specified in these Schedules.
LEAD COMPOUNDS for human therapeutic use.
LEFETAMINE
LEFLUNOMIDE
LENOGRASTIM
LEPIRUDIN
LEPTAZOL
LERCANIDIPINE
LETROZOLE
LEUPRORELIN
LEVALLORPHAN

LEVAMISOLE –
(a) for human therapeutic use; or
(b) in preparations for the prevention or treatment of heartworm in dogs.

LEVETIRACETAM
LEVOBUNOLOL
LEVOBUPIVACAINE
LEVOCABASTINE except when included in Schedule 2.
LEVODOPA
LEVONORGESTREL
LIDOFLAZINE
LIGNOCAINE except when included in Schedule 1.
LINCOMYCIN
LINDANE for human therapeutic use except when included in Schedule 1.
LIOTHYRONINE SODIUM (Triiodothyronine).
LISINOPRIL
LISURIDE
LITHIUM salts for therapeutic use, except in preparations containing 0.01 per cent or less of lithium.
LODOXAMIDE except when included in Schedule 2.
LOFEXIDINE
LOMEFLOXACIN
LOMUSTINE
LOPERAMIDE except when included in Schedule 2.
LOPINAVIR
LOPRAZOLAM
LORCARBEF
LORATADINE except when included in Schedule 2.
LORAZEPAM
LORMETAZEPAM
LOSARTAN
LOXAPINE
LUMEFANTRINE
# LUTEINISING HORMONE (See also gonadotrophins).
LYMECYCLINE
MAFENIDE
MAGNESIUM SULPHATE as a preparation for injection.
MANDRAGORA OFFICINARIUM
MANNITOL injection.

MALDISON for human therapeutic use except when included in Schedule 1 or 2.

MANNOMUSTINE
MAPROTILINE
MARBOFLOXACIN
MAZINDOL
MEASLES VACCINE
MEBANAZINE
MEBEVERINE
MEBHYDROLIN
# MEBOLAZINE
MEBUTAMATE
MECAMYLAMINE
MESCASERMIN
MECILLIN
MECLOCYCLINE
MECLOFENAMATE
MECLOFENOXATE
MECLOZINE
MEDAZEPAM
MEDETOMIDINE
MEDIGOXIN (methyldigoxin)
MEDROXYPROGESTERONE
MEDRYSONE
MEFENAMIC ACID except when included in Schedule 2.
MEFENOREX
MEFLOQUINE
MEFRUSIDE
MEGESTROL
MELATONIN
MELENGESTROL except when used as an animal feed additive.
MELOXICAM
MELPHALAN
MEMANTINE
MENINGOCOCCAL VACCINE
MENOTROPIN
MEPACRINE
MEPENZOLATE
MEPHENESIN and its derivatives except guaiphenesin where specified in Schedule 1 or 3.
MEPHENTERMINE
MEPINDOLOL
# MEPITIOSTANE
MEPIVACAINE
MEPROBAMATE
MEPYRAMINE except when included in Schedule 2.
MERCEPTOMERIN
MERCAPTOPURINE and other substances structurally derived therefrom with cytotoxic properties when used for therapeutic purposes.
MERCUROUS CHLORIDE for internal therapeutic use.

MERCURY ORGANIC COMPOUNDS for cosmetic or therapeutic use except when included in Schedule 1.

MEROPENEM
MERSALYL
# MESABOLONE
MESALAZINE
MESNA
# MESTANOLONE (androstalone)
# MESTEROLONE
MESTRANOL
METARAMINOL
# METENOLONE
METERGOLINE
METFORMIN
METHACHOLINE SALTS
METHACYCLINE
METHALLENOESTRIL
# METHANDIENONE (metandienone)
# METHANDRIOL
METHANTHELINIUM
METHAZOLAMIDE
METHDILAZINE except when included in Schedule 2.
# METHENOLONE
METHICILLIN
METHIMAZOLE
METHISAZONE
METHIXENE
METHOCARBAMOL
METHOHEXITONE
METHOIN
METHOTREXATE
METHOTRIMEPRAZINE
METHOXAMINE preparations for injection.
METHOXSALEN.
METHOXYFLURANE for therapeutic use.
METHSUXIMIDE.
METHYCLOTHIAZIDE.
METHYL AMINOLEVULINATE.
METHYLANDROSTANOLONE.
# METHYLCLOSTEBOL.
METHYLENE BLUE in preparations for injection.
METHYLDOPA.
METHYLERGOMETRINE
METHYLPENTYNOL and other substituted alkynes for internal use.
METHYLPHENOBARBITONE
METHYLPREDNISOLONE
# METHYLTESTOSTERONE
METHYLTHIOURACIL
# METHYLTRIENOLONE
METHYPRYLONE
METHYSERGIDE
METOCLOPRAMIDE except when included in Schedule 2.
METOLAZONE
METOPROLOL
# METRIBOLONE
METRIFONATE (trichlorfon)
METRIZAMIDE
METRONIDAZOLE including benzoylmetronidazole.
METYRAPONE
MEXILETINE
MEZLOCILLIN
MIANSERIN
MIBEFRADIL
# MIBOLERONE
MICONAZOLE except when included in Schedule 2.
MIDAZOLAM.
MIDODRINE.
MIGLITOL

MILBEMYCIN OXIME except when included in Schedule 1.

MILRINONE
MINOCYCLINE
MINOXIDIL except when included in Schedule 2.
MIRTAZEPINE.
MISOPROSTOL.
MITOBRONITOL.
MITOMYCIN.
MITOTANE.
MITOZANTRONE.
MIVACURIUM CHLORIDE.
MOCLOBEMIDE.
MODAFINIL.
MOLGRAMOSTIM.
MOLINDONE.
MOMETASONE except when included in Schedule 2.
MONENSIN except –in animal feeds containing 33 mg/kg or less of antibiotic substances.

MONOAMINE OXIDASE INHIBITORS, including iproniazid, isocarboxazid, nialamide, phenelzine, pheniprazine and other preparations for which monoamine oxidase inhibition is claimed, except triparanol.
MONOBENZONE for human therapeutic use except in preparations containing 2 per cent or less of monobenzone.

MONOCLONAL ANTIBODIES for therapeutic use except
in diagnostic kits; or
when separately mentioned in this Schedule.

MONTELUKAST.
MOPERONE.
MORAZONE.
MORICIZINE.
MOTRAZEPAM.
MOTRETINIDE.
MOXIDECTIN in preparations for injection containing 10 per cent or less of moxidectin.
MOXIFLOXACIN
MUMPS VACCINE
MUPIROCIN
MUROMONAB
MUSTINE and other substances structurally derived therefrom with cytotoxic properties, when used for therapeutic purposes except when specified in this Schedule.
MYCOPHENOLIC ACID
NABUMETRONE
NADOLOL
NADROPARIN
NAFARELIN
NAFTIDROFURYL
NALBUPHINE
NALIDIXIC ACID
NALORPHINE
NALOXONE
NALTREXONE
# NANDROLONE
NAPROXEN except when included in Schedule 2.
NARASIN except –in animal feeds containing 100 mg/kg or less of narasin.
NARATRIPTAN
NATAMYCIN
NATEGLINIDE
NEBACUMAB
NEDOCROMIL
NEFAZODONE
NEFOPAM
NELFINIVIR (included nelfinivir mesylate)
NEOMYCIN
NEOSTIGMINE
NERIUM OLEANDER
NETILMICIN
NEVIRAPINE
NIALAMIDE
NICARDIPINE
NICERGOLINE

NICOCODINE when compounded with one or more other medicaments –
(a) in divided preparations containing not more than 100 mg of nicocodine

per dosage unit; or
(b) in undivided preparations with a concentration of not more than 2.5 per cent of nicocodine.

NICODICODINE when compounded with one or more other medicaments –
(a) in divided preparations containing not more than 100 mg of nicodicodine per dosage unit; or
(b) in undivided preparations with a concentration of not more than 2.5 per cent of nicodicodine.

NICOFURANOSE
NICORANDIL
NICOTINE for use as an aid in withdrawal from tobacco smoking except when included in Schedule 2.
NICOTINIC ACID for human therapeutic use except when included in Schedule 2.
NICOTINYL ALCOHOL for internal use.
NICOUMALONE for internal therapeutic use.
NIFEDIPINE
NIFENAZONE
NIFURSOL
NIKETHAMIDE
NILUTAMIDE
NIMESULPRIDE
NIMODIPINE
NIMORAZOLE
NIRIDAZOLE
NISOLDIPINE
NITRAZEPAM
NITRENDIPINE
NITROFURAN and its derivatives for human therapeutic use except when included in Schedule 2.
NITROFURANTOIN
NITROFURAZONE
NITROUS OXIDE for therapeutic use.
NITROXOLINE
NIZATADINE except when included in schedule 2.
NOMIFENSINE
NORADRENALINE (excluding its derivatives).

NORCODEINE when compounded with one or more other medicaments –
(a) in divided preparations containing not more than 100 mg of norcodeine per dosage unit; or
(b) in undivided preparations with a concentration of not more than 2.5 per cent of norcodeine.

# 19-NORANDROSTENEDIOL.
# 19-NORANDROSTENEDIONE.
# NORANDROSTENOLONE.
# NORBOLETHONE.
# NORCLOSTEBOL.
# NORETHANDROLONE
NORETHISTERONE.
NORFLOXACIN
NORGESTEROL.
# NORMETHANDRONE.
NORTRIPTYLINE
NOVOBIOCIN
NOXIPTYLINE
NYSTATIN except when included in Schedule 2.
OCTAMYLAMINE
OCTATROPINE
OCTREOTIDE
OCTYL NITRITE
OESTRADIOL except in implant preparations for growth production in animals.
OESTRIOL
OESTROGENS except when separately specified in these schedules.
OESTRONE
OFLOXACIN
OLANZAPINE
OLEANDOMYCIN except – in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.
OLENDRIN
OLOPATADINE
OLSALAZINE
OMALIZUMAB
OMEPRAZOLE
ONDANSETRON
OPIPRAMOL
ORCIPRENALINE

ORGANOPHOSPHORUS COMPOUNDS with anticholinesterase activity for human therapeutic use except –
(a) when included in Schedule 1; or
(b) when separately specified in this Schedule.

ORLISTAT
ORNIDAZOLE
ORNIPRESSIN
ORPHENADRINE
ORTHOCAINE
ORTHOPTERIN
OSELTAMIVIR
OUABAIN
# OVANDROTONE
# OXABOLONE
OXACILLIN
OXALIPLATIN
# OXANDROLONE
OXAPROZIN
OXAZEPAM
OXCARBAZEPINE
OXEDRINE for human internal use except in preparations labelled with a recommended daily dose of 30mg or less of oxedrine.
OXETACAINE
OXICONAZOLE
OXITROPIUM SALTS
OXOLAMINE
OXOLINIC ACID
OXPRENOLOL
OXYBUPROCAINE
OXYBUTYNIN
# OXYMESTERONE
# OXYMETHOLONE
OXPENTIFYLLINE
OXYPHENBUTAZONE
OXYPHENCYCLIMINE
OXYPHENONIUM
OXYTETRACYCLINE
OXYTOCIN
PACLITAXEL
PALIVIZUMAB
PAMAQUINE
PAMIDRONIC ACID
PANCREATIC ENZYMES
PANCURONIUM
PANTOPRAZOLE
PARACETAMOL when combined with aspirin, caffeine or salicylamide or any derivative of these substances.
PARALDEHYDE
PARAMETHADIONE
PARAMETHASONE
PARECOXIB
PAROMOMYCIN
PAROXETINE
PECAZINE
PEGFILGRASTIM
PEFLOXACIN
PEMOLINE
PEMPIDINE
PENBUTOLOL
PENCICLOVIR except when included in Schedule 2.
PENETHAMATE
d-PENICILLAMINE
PENTAGASTRIN
PENTAMETHONIUM
PENTAMIDINE
PENTHIENATE
PENTOBARBITONE when packed and labelled for injection.
PENTOLINIUM
PENTOSAN POLYSULPHATE SODIUM
PERGOLIDE
PERHEXILENE
PERICYAZINE
PERINDOPRIL
PERPHENAZINE
PERTUSSIS ANTIGEN
PHENACEMIDE
PHENACETIN for therapeutic use.
PHENACEMIDE
PHENAGLYCODOL
PHENAZONE except when included in Schedule 2.
PHENAZOPYRIDINE
PHENELZINE
PHENETHICILLIN
PHENFORMIN
PHENGLUTARIMIDE
PHENINDIONE for internal therapeutic use.
PHENIRAMINE except when included in Schedule 2.
PHENOBARBITONE
PHENOL in preparations for injection.
PHENOLPHTHALEIN for human therapeutic use.
PHENOXYBENZAMINE
PHENOXYMETHYLPENICILLIN except when included in Schedule 2.
PHENSUXIMIDE and other substances structurally derived from succinamide with anticonvulsant properties when used for therapeutic purposes.
# PHENTERMINE
PHENTHIMENTONIUM
PHENTOLAMINE
PHENYLBUTAZONE
PHENYLEPHRINE in preparations for human ophthalmic use containing 5 per cent or more of phenylephrine and except when included in Schedule 2.
PHENYLPROPANOLAMINE except when included in Schedule 2.
PHENYLTOLOXAMINE except when included in Schedule 2.
PHENYTOIN and other substances structurally derived from hydantoin with anticonvulsant properties when used for therapeutic purposes.

PHOLCODINE when compounded with one or more other medicaments –
(a) in divided preparations containing not more than 100 mg of pholcodine per dosage unit; or
(b) in undivided preparations with a concentration of not more than 2.5 per cent of pholcodine;
except when included in Schedule 2

PHTHALYLSULPHATHIAZOLE
PHYSOSTIGMINE
PICROTOXIN
PILOCARPINE except in preparations containing 0.025 per cent or less of pilocarpine.
PIMECROLIMUS
PIMOBENDAN
PIMOZIDE
PINACIDIL
PINDOLOL
PIOGLITAZONE
PIPECURONIUM BROMIDE
PIPEMIDIC ACID
PIPENZOLATE
PIPERACILLIN
PIPERIDINE
PIPERIDOLATE
PIPOBROMAN
PIPOTHIAZINE
PIPRADROL
PIRBUTEROL
PIRENZEPINE
PIRETANIDE
PIRFENOXONE SODIUM (catalin)
PIROXICAM
PIRPROFEN
PITUITARY, its extracts and active principles or their synthetic substitutes except when separately specified in this Schedule.
PIVAMPICILLIN
PIZOTIFEN
PLICAMYCIN
PNEUMOCOCCAL VACCINE
PODOPHYLLOTOXIN for human use.
PODOPHYLLUM EMODI
PODOPHYLLUM PELTATUM
PODOPHYLLUM RESIN (Podophyllin) for human therapeutic use except when included in Schedule 2.
POLIDEXIDE
POLIOMYELITIS VACCINE
POLYACRYLAMIDE
POLYGELINE
POLYLACTIC ACID in preparations for injection or implantation for human use.
POLYESTRADIOL
POLYMETHYLENE BISTRIMETHYL AMMONIUM COMPOUNDS
POLYMYXIN
POLYSULPHATED GLYCOSAMINOGLYCANS in preparations for injection, except where otherwise specified in this Schedule.
POLYTHIAZIDE
POTASSIUM BROMIDE for therapeutic use.
POTASSIUM CHLORIDE injection
POTASSIUM PERCHLORATE for therapeutic use.
PRACTOLOL
PRALIDOXIME
PRAMIPEXOLE
PRAMPINE SALTS
PRAMOXINE (pramocaine) except when included in Schedule 2.
# PRASTERONE (dehydroepiandrosterone, dehydroisoandrosterone)
PRAVASTATIN.
PRAZEPAM.
PRAZIQUANTEL for human therapeutic use.
PRAZOSIN
PREDNISOLONE
PREDNISONE
PREGNENOLONE ACETATE except in preparations for topical use.
PRENALTEROL
PRENYLAMINE
PRILOCAINE except when included in Schedule 2.
PRIMAQUINE
PRIMIDONE
PROBENECID
PROBUCOL
PROCAINAMIDE
PROCAINE
PROCAINE PENICILLIN
PROCARBAZINE
PROCHLORPERAZINE except when included in Schedule 2.
PROCYCLIDINE except when included in Schedule 2.
PROGESTERONE except for use in animals.
PROGESTOGENS except when separately specified in these schedules.
PROGLUMIDE
PROGUANIL
PROLINTANE
PROMAZINE
PROMETHAZINE except when included in Schedule 2.
PROMOXOLONE
PROPAFENONE
PROPANIDID
PROPANTHELINE PROPENTOFYLLINE
# PROPETANDROL
PROPIONIBACTERIUM ACNES
PROPOFOL
PROPOXUR for human therapeutic use.
PROPRANOLOL
#PROPYLHEXEDRINE except when included in Schedule 2.
PROPYLTHIOURACIL
PROPYHENAZONE
PROQUAZONE
PROSCILLARIDIN
PROSTAGLANDINS except where separately specified in this Schedule.
PROSTIANOL
PROTAMINE SULPHATE except when included in insulins.
PROTHIONAMIDE
PROTHIONAMIDE
PROTHIPENDYL
PROTIRELIN (thyrotrophin releasing factor)
PROTOVERATRINES
PROTRIPTYLINE
PROXYMETACAINE
PSEUDOEPHEDRINE in preparations for stimulant, appetite suppression or weight control purposes except when included in Schedule 2.
PYRAZINAMIDE
PYRIDINOLCARBAMATE
PYRIDOSTIGMINE

PYRIDOXINE HYDROCHLORIDE, PYRIDOXAL, or PYRIDOXAMINE
in preparations for human use containing more than 50 mg of pyridoxine per recommended daily dose unless labelled with the warning statement "WARNING - THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD”.

PYRIMETHAMINE except when included in Schedule 2 (see Sulfadoxine with Pyrimethamine entry)
PYROVALERONE
QUAZEPAM
QUETIAPINE
QUINAGOLIDE
QUINAPRIL
# QUINBOLONE
QUINETHAZONE
QUINIDINE
QUININE except when included in Schedule 2.
QUINISOCAINE (dimethisoquin)
QUINUPRISTIN
RABEPRAZOLE
RABIES VACCINE
RACTOPAMINE except in animal feed premixes containing 10 per cent or less
of ractopamine.
RALOXIFENE
RALTITREXED
RAMIPRIL
RANITIDINE except when included in Schedule 2.
RAPACURONIUM BROMIDE.
RASBURICASE
RAUWOLFIA SERPENTINA
RAUWOLFIA VOMITORIA
RAZOXANE
REBOXITINE
REMOXIPRIDE
REPAGLINIDE
RESERPINE
RETEPLASE
RIBAVIRIN
RIFABUTIN
RIFAMPICIN (rifamycin)
RILUZOLE
RIMITEROL HYDROBROMIDE
RISEDRONIC ACID
RISPERIDONE
RITODRINE
RITONAVIR
RITUXIMAB
RIVASTIGMINE
RIZATRIPTAN
ROCURONIUM BROMIDE
ROFECOXIB
ROLITETRACYCLINE
ROMIFIDINE
RONIDAZOLE
ROPINIROLE
ROPIVACAINE
ROSIGLITAZONE
ROSOXACIN
ROSUVASTATIN
# ROXIBOLONE
ROXITHROMYCIN
RUBELLA VACCINE
SALBUTAMOL except when included in Schedule 2.
SALCATONIN
SALICYLAMIDE when combined with aspirin, caffeine or paracetamol or any derivative of these substances.
SALINOMYCIN except -in animal feeds containing 60 mg/kg or less of antibiotic substances.
SALMETEROL
SAQUINAVIR
SCHOENOCAULON OFFICINALE (sabadilla)
SCOPOLIA CARNIOLICA
SELEGILINE

SELENIUM except –
(a) as selenium arsenide in photocopier drums; or
(b) in animal feeds containing 0.1 g/tonne or less of selenium; or
(c) in compressed pellets for control of selenium responsive conditions

in sheep or cattle; or
(d) in fertilizers containing 200 g/tonne or less of selenium; or
(e) in preparations for human oral use with a recommended daily dose

of 100mcg or less of selenium except where the sum of the organic selenium expressed in mcg and half the inorganic selenium expressed in mcg, contained in the recommended daily dose of the preparation does not exceed 26 mcg.

SEMISODIUM VALPROATE
SERMORELIN
SERTINDOLE
SERTRALINE
SEVOFLURANE
SEX HORMONES and all substances having sex hormonal activity except when separately specified in these Schedules.
SIBUTRAMINE
# SILANDRONE
SILDENAFIL
SILICONES in injectable preparations for human use except when separately specified in these Schedules.
SILVER SULPHADIAZINE
SIMVASTATIN
SIROLIMUS
SISOMYCIN
SODIUM BICARBONATE as a preparation for injection.
SODIUM BROMIDE
SODIUM CELLULOSE PHOSPHATE for human internal use.
SODIUM CROMOGLYCATE except when included in Schedule 2.
SODIUM MORRHUATE in preparations for injections.
SODIUM NITROPRUSSIDE for human therapeutic use.
SODIUM POLYSTYRENE SULPHONATE
SODIUM SALICYLATE in preparations for injections for treatment of animals.
SODIUM PHOSPHATE in preparations for oral laxative use.
SODIUM TETRADECYLSULFATE in preparations for injections.
SODIUM VALPROATE
SOLASODINE
SOMATOSTATIN.
SOMATOTROPIN EQUINE
SOMATROPIN (human growth hormone).
SONTOQUINE
SOTALOL
SPARFLOXACIN
SPARTEINE
SPECTINOMYCIN except in animal feeds for growth production in pigs or poultry, containing 50mg/kg or less of antibiotic substances.
SPIRAMYCIN except – in animal feeds for growth promotion in pigs or poultry containing 50 mg/kg or less of antibiotic substances.
SPIRAPRIL
SPIRONOLACTONE
SPUTOLYSIN - trans-4-(3,5-bibroma-2-hydroxybenzyl)-amino cyclohexanol hydrochloride monohydrate.
# STANOLONE
# STANOZOLOL
STAVUDINE
# STENBOLONE
STEROID HORMONES except when separately specified in these Schedules.
STILBOESTROL
SREPTODORNASE
STREPTOKINASE
STREPTOMYCIN
STROPHANTHIN-K
STROPHANTHUS and its glycosides.
STRYCHNINE in preparations containing 1.5 per cent or less of strychnine for the treatment of animals.
STRYCHINOS spp.
STYRAMATE
SULBACTAM
SULCONAZOLE except when in Schedule 2
SULFACETAMIDE except when included in Schedule 1 or 2.
SULFADIAZINE except when included in Schedule 1.
SULFADIMETHOXINE
SULFADIMIDINE except when included in Schedule 1.
SULFADOXINE except when included in Schedule 2.
SULFAFURAZOLE
SULFAGUANIDINE
SULFAMERAZINE except when included in Schedule 1.
SULFAMETHIZOLE
SULFAMETHOXAZOLE except when included in Schedule 2 as Cotrimoxazole.
SULFAMETHOXYDIAZINE
SULFAMETHOXYPYRIDAZINE
SULFAMETROLE
SULFAMONOMETHOXINE
SULFAMOXOLE
SULFAPHENAZOLE
SULFAPYRIDINE
SULFAQUINOXALINE
SULFASALAZINE
SULFATHIAZOLE except when included in Schedule 1.
SULPHONAMIDES except when separately specified in these Schedules.
SULFONMETHANE (sulfonal) and alkyl sulfonals.
SULINDAC

SULPHANILAMIDE and its derivatives except – sulphonamide
(a) when separately specified in this Schedule; or
(b) oryzalin; or
(c) sulphaquinoxaline in animal feeds containing 200 mg/kg or less of sulphaquinoxaline; or
(d) sulphaquinoxaline when incorporated in baits for the destruction of vermin.

SULPHATROXAZOLE
SULPHINPYRAZONE
SULPHOMYXIN
SULPHONAL and alkyl sulphonals.
SULTAMICILLIN
SULTHIAME
SUMATRIPTAN
SUBROFEN
SUTILAINS
SUXAMETHONIUM SALTS
SUXETHONIUM BROMIDE
TACRINE
TACROLIMUS
TADALAFIL
TAMOXIFEN
TAMSULOSIN
TANACEUM VULGARE except in preparations containing 0.8 per cent or less of oil of tansy
TASONERMIN
TAZAROTENE
TAZOBACTAM
T-CELL RECEPTOR ANTIBODY
TEGAFUR
TEGASEROD
TEICOPLANIN
TELITHROMYCIN
TELMISARTAN
TEMAZEPAM
TEMOZOLOMIDE
TENECTEPLASE
TENIPOSIDE
TENOFOVIR
TENOXICAM
TEPOXALIN
TERAZOSIN
TERBINAFINE except when included in Schedule 2.
TERBUTALINE except when included in Schedule 2.
TERFENADINE
# TERIPARATIDE
TERODILINE
TEROPTERIN
# TESTOLACTONE
# TESTOSTERONE except when included in Schedule 1.
TETANUS ANTITOXIN except when used for short-term protection or treatment of tetanus in animals.
TETANUS TOXOID for human use.
TETRABENAZINE
TETRACOSACTRIN
TETRACYCLINE except when included in Schedule 2.
TETRAETHYLAMMONIUM SALTS.
TETROXOPRIM

# THALIDOMIDE (The prescriber must, where the patient is a woman of child-bearing age:
(a) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and
(b) advise the patient to avoid becoming pregnant during or for a period of one month after completion of treatment.)

THENYLDIAMINE except when included in Schedule 2.
THEOPHYLLINE except when included in Schedule 2.
THIEVETIA PERUVIANA
THEVETIN
THIACETARSAMIDE, in preparations for the prevention or treatment of heart worm in dogs.
THIACETAZONE
THIAMBUTOSINE
THIAZOSULPHONE
THIETHYLPERAZINE
THIOCARLIDE
THIOGUANINE
# THIOMESTERONE (tiomesterone)
THIOPENTONE
THIOPROPAZATE
THIOPROPERAZINE
THIORIDAZINE
THIOSTREPTON
THIOTEPA and other substances structurally derived therefrom with cytotoxic properties when used for therapeutic purposes.
THIOTHIXENE
THIOURACIL and substances structurally derived therefrom with antithyroid properties when used for therapeutic purposes.
THIOUREA for therapeutic use.
THYMOXAMINE
THYROID and extracts, and its active principles except when separately specified in this Schedule.
THYROTROPHIN (T.S.H.)
THYROXINE SODIUM
TIAGABINE
TIAMULIN except – in prepared animal feeds.
TIAPROFENIC ACID
TIARAMIDE
TIBOLONE
TICARCILLIN
TICLOPIDINE
TIEMONIUM
TIENILIC ACID
TIGLOIDINE
TILETAMINE
TILMICOSIN
TILUDRONIC ACID
TIMOLOL
TINIDAZOLE
TINZAPARIN
TIOCONAZOLE except when in Schedule 2.
TIOPROPIUM
TIPEPIDINE
TIRILAZAD
TIROFIBRAN HYDROCHLORIDE
TOBRAMYCIN
TOCAINIDE
TOLAZAMIDE
TOLAZOLINE for internal use.
TOLBUTAMIDE
TOLCAPONE
TOLFENAMIC ACID.
TOLMETIN.
TOLONIUM CHLORIDE.
TOLPROPAMINE.
TOLRESTAT.
TOLTERODINE TARTRATE.
TOPIRAMATE.
TOPOTECAN.
TORASEMIDE.
TOREMIFENE.
TOXOIDS.
TRAMADOL.
TRANDOLAPRIL.
TRANEXAMIC ACID except when included in Schedule 2.
TRANYLCYPROMINE
TRASTUZUMAB
TRAVOPROST
TRAZADONE
# TRENBOLONE
TREPROSTINIL
TREOSULPHAN
# TRESTOLONE
TRETAMINE
# TRETINOIN for external human therapeutic use.
TRIACETYLOLEANDOMYCIN
TRIAMCINOLONE except when included in Schedule 2.
TRIAMTERENE
TRIAZIQUONE
TRIAZOLAM
TRICHLORMETHIAZIDE
TRICHLOROACETIC ACID for human dermal use except when in preparations containing 12.5 per cent of less of trichloroacetic acid for the treatment of warts other than anogenital warts.
TRICHLOROETHYLENE for therapeutic use.
TRICLOFOS
TRICYCLAMOL
TRIDIHEXETHYL
TRIFLUOPERAZINE
TRIFLUPERIDOL
TRIFLUPROMAZINE
TRIMEPRAZINE except when included in Schedule 2.
TRIMETAPHAN
TRIMETHOPRIM except when included in Schedule 2 as Cotrimoxazole.
TRIMIPRAMINE
TRIMUSTINE
TRIOXYSALEN
TRIPELENNAMINE
TRIPLE ANTIGEN VACCINE
TRIPROLIDINE except when included in Schedule 2.
TRIPTORELIN
TROGLITAZONE
TROMETAMOL in preparations for injection.
TROPICAMIDE
TROPISETRON
TROVAFLOXACIN
TROXIDONE and other substances structurally derived from oxazolidinone with anticonvulsant properties when used for therapeutic purposes.
TRYPTOPHAN
TUBOCURARINE
TULOBUTEROL

TYLOSIN except –
(a) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances; or
(b) in milk replacers for calves or starter rations for pigs, containing 100 mg/kg or less of antibiotic substances.

TYPHOID VACCINE
UNOPROSTONE
URACIL
URAPIDIL
URETHANE (excluding its derivatives) for therapeutic use.
URETHANES AND UREIDES having or purporting to have soporific, hypnotic or narcotic properties except when separately specified in this Schedule.
# UROFOLLITROPHIN.
UROKINASE.
URSODEOXYCHOLIC ACID.
VACCINES, sera, toxoids, and antigens for human parenteral use.

VACCINES, veterinary live virus except –
(a) poultry vaccines; or
(b) pigeon pox vaccine; or
(c) scabby mouth vaccine.

VALACICLOVIR
VALDECOXIB
VALGANCICLOVIR
VALNOCTAMIDE
VALSARTAN
VANCOMYCIN
VARDENAFIL
VARICELLA VACCINE
VASOPRESSIN
VECURONIUM
VEDAPROFEN
VENLAFAXINE
VERAPAMIL
VERATRUM for therapeutic use.
VERTEPROFIN
VIDARABINE
VIGABATRIN
VILOXAZINE
VINBLASTINE
VINCAMINE
VINCRISTINE
VINCA ALKALOIDS including semi-synthetic derivatives.
VINDESINE
VINORELBINE
VINYL ETHER for anaesthesia.
VIPRYNIUM
VIRGINIAMYCIN except in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.
VISNADINE
VITAMIN A for human therapeutic use, except in preparation containing 10,000 I.U. or less of vitamin A per recommended daily dosage.
VITAMIN D for human therapeutic use, except in preparations containing 25 micrograms or less of vitamin D per recommended daily dosage.
VORICONAZOLE
WARFARIN for internal therapeutic use.
XAMOTEROL
XANTHINOL NICOTINATE
XIPAMIDE
XYLAZINE
YOHIMBINE
ZAFIRLUKAST
ZALCITABINE
ZALEPLON
ZANAMIVIR
ZERANOL
ZIDOVUDINE
ZILPATEROL
ZIMELDINE
ZINC COMPOUNDS for human internal use except when included in Schedules 1 and 2.
ZIPRASIDONE
ZOLAZEPAM
ZOLEDRONIC ACID
ZOLMITRIPTAN
#ZOLPIDEM
#ZOPICLONE
ZOXAZOLAMINE
ZUCLOPENTHIXOL

Table of Amendments

1 Amended by Order 32 of 2005
2 Substituted by Order 32 of 2005
2A Inserted by Order 32 of 2005
Schedules 1,2,3 Substituted by Order 32 of 2005

8 August 2005

PRINCIPAL PHARMACIST’S NOTICE

Published Gazette No. 25 of 2005
(pursuant to the Sale of Medicines Regulations, Regulation 3)

All medicines which are not mentioned in the Schedules but are of a similar family type of medicine as a medicine which is listed in the Schedules will automatically be included in the Schedules until such time as they are separately listed.

All medicines which are not included in the Schedule will assume the corresponding status according to the Standard for the Uniform Scheduling of Drugs and Poisons (SUSDP)** in Australia unless otherwise stated in this Act.

All medicines labelled # require special authorisation from the Principal Pharmacist before importation or supply of these medicines is allowed.

^[1] Editor’s note: A Principal Pharmacist’s Notice was published in August 2005. This Notice follows the Schedules to these Regulations.